Researcher Profile and Settings

Master

Affiliation (Master)

• Hokkaido University Hospital　Surgery

Affiliation (Master)

• Hokkaido University Hospital　Surgery

researchmap

Profile and Settings

Affiliation

• Hokkaido University, Hokkaido University Hospital, Associate Professor

Profile and Settings

• Name (Japanese)

  Masato

• Name (Kana)

  Aragaki

• Name

  201701012245083806

Affiliation

• Hokkaido University, Hokkaido University Hospital, Associate Professor

Achievement

Research Interests

• Oncogene   悪性胸膜中皮腫   Lung cancer   Photodynamic therapy   Thoracic surgery   

Research Areas

• Life sciences / Tumor diagnostics and therapeutics / Photodynamic Therapy
• Life sciences / Genomics
• Nanotechnology/Materials / Nanobioscience / nanoparticles
• Nanotechnology/Materials / Molecular biochemistry
• Life sciences / Respiratory surgery

Research Experience

• 2023/04 - Today Hokkaido University Hospital Thoracic surgery
• 2022/01 - 2023/12 Toronto General Hospital Thoracic surgery Lung transplant clinical fellow
• 2019/04 - 2021/12 University of Toronto Latnar thoracic surgery reserach laboratories
• 2017/04 - 2019/03 Hokkaido University Hospital
• 2008/04 - 2011/03 The Institute of Medical Science, the University of Tokyo The Institute of Medical Science Human Genome Center Laboratory of Molecular Medicine

Education

• 2007/04 - 2013/03  Hokkaido University  Graduate School of Medicine
• 1997/04 - 2003/03  Hokkaido University  School of Medicine

Published Papers

• Clinical and pathological predictors of engraftment for patient-derived xenografts in lung adenocarcinoma.

  Hiroyuki Ogawa, Takamasa Koga, Nhu-An Pham, Nicholas Bernards, Alexander Gregor, Yuki Sata, Shinsuke Kitazawa, Yoshihisa Hiraishi, Tsukasa Ishiwata, Masato Aragaki, Fumi Yokote, Andrew Effat, Kate Kazlovich, Quan Li, Katrina Hueniken, Ming Li, Yoshimasa Maniwa, Ming-Sound Tsao, Kazuhiro Yasufuku

  Lung cancer (Amsterdam, Netherlands) 194 107863 - 107863 2024/08 

  Patient-derived xenografts (PDXs) are increasingly utilized in preclinical drug efficacy studies due to their ability to retain the molecular, histological, and drug response characteristics of patient tumors. This study aimed to investigate the factors influencing the successful engraftment of PDXs. Lung adenocarcinoma PDXs were established using freshly resected tumor tissues obtained through surgery. Radiological data of pulmonary nodules from this PDX cohort were analyzed, categorizing them into solid tumors and tumors with ground-glass opacity (GGO) based on preoperative CT images. Gene mutation status was obtained from next generation sequencing data and MassARRAY panel. A total of 254 resected primary lung adenocarcinomas were utilized for PDX establishment, with successful initial engraftment in 58 cases (22.8 %); stable engraftment defined as at least three serial passages was observed in 43 cases (16.9 %). The stable engraftment rates of PDXs from solid tumors and tumors with GGO were 22.1 % (42 of 190 cases) and 1.6 % (1 of 64 cases), respectively (P < 0.001). Adenocarcinomas with advanced stage, poor differentiation, solid histologic subtype, and KRAS or TP53 gene mutations were associated with stable PDX engraftment. Avoiding tumors with GGO features could enhance the cost-effectiveness of establishing PDX models from early-stage resected lung adenocarcinomas.
• A successful 24-hour preservation for human lung lobar transplantation leveraging 10 ° cold storage and ex vivo lung perfusion

  Masato Aragaki, Terunaga Inage, Mitsuaki Kawashima, Daisuke Taniguchi, Tatsuya Kato, Kazuhiro Yasufuku, Shaf Keshavjee, Marcelo Cypel

  JTCVS Techniques 26 159 - 162 2666-2507 2024/08
• ラット虚血再灌流傷害モデルを用いた新規抗炎症薬による肺傷害抑制効果の検討

  椎谷 洋彦, 千葉 龍平, 渡辺 正明, 大塚 将平, 佐々木 明洋, 大高 和人, 氏家 秀樹, 藤原 晶, 新垣 雅人, 加藤 達哉

  移植 (一社)日本移植学会 59 (1) 88 - 88 0578-7947 2024/07
• 肺移植クラウドファンディングを経験して

  加藤 達哉, 大塚 将平, 佐々木 明洋, 椎谷 洋彦, 大高 和人, 藤原 晶, 氏家 秀樹, 新垣 雅人

  移植 (一社)日本移植学会 59 (1) 101 - 101 0578-7947 2024/07
• Impact of pulmonary vein-first ligation during lobectomy on the postoperative survival and recurrence rates in patients with non-small cell lung cancer: a multicenter propensity score-matched study.

  Haruhiko Shiiya, Hideki Ujiie, Ryohei Chiba, Shunsuke Nomura, Kazuto Ohtaka, Aki Fujiwara-Kuroda, Masato Aragaki, Keita Takahashi, Kazufumi Okada, Tatsuya Kato

  Surgery today 2024/05/30 

  PURPOSE: Surgical manipulation of the lungs increases the number of circulating tumor cells and the subsequent risk of metastasis in patients with lung cancer. This study investigated whether or not ligating the tumor-draining pulmonary vein first during lobectomy could improve the prognosis of these patients. METHODS: We retrospectively evaluated patients who underwent curative lobectomy for solitary nonsmall-cell lung carcinoma between January 2012 and December 2016. We divided the patients into the vein-first group, in which all associated pulmonary veins were dissected and severed before cutting the pulmonary artery, bronchus, or pulmonary fissure, and the other procedure group. RESULTS: Overall, we included 177 and 413 patients in the vein-first and other procedure groups, respectively. Propensity score matching yielded 67 pairs of patients. The 5-year overall survival (85.6% [95% confidence interval, 77.3-94.8%] vs. 69.4% [58.7-81.9%], P = 0.03%) and recurrence-free survival (73.4% [63.3-85.1%] vs. 53.5% [42.5-67.3%], P = 0.02) were significantly better in the vein-first group than in the other procedure group. The cumulative recurrence rate at 5 years post-surgery was significantly lower in the vein-first group than in the other procedure group (21.7% vs. 38.3%, P = 0.04). CONCLUSION: Our study suggests that ligating the pulmonary vein first during lobectomy for lung cancer can improve the overall survival, recurrence-free survival, and cumulative recurrence rate.
• Dose Optimization of Intravenous Indocyanine Green for Malignant Lung Tumor Localization

  Hideki Ujiie, Ryohei Chiba, Akihiro Sasaki, Shunsuke Nomura, Haruhiko Shiiya, Shohei Otsuka, Hiroshi Yamasaki, Aki Fujiwara-Kuroda, Kazuto Ohtaka, Masato Aragaki, Kazufumi Okada, Yuma Ebihara, Tatsuya Kato

  Journal of Clinical Medicine 13 (10) 2807 - 2807 2024/05/10 

  Background: Intravenously administered indocyanine green (ICG) accumulates in lung tumors, facilitating their detection via a fluorescence spectrum measurement. This method aids in identifying tumor locations that are invisible to the naked eye. We aim to determine the optimal ICG dose and administration method for accurate tumor identification during lung resection surgeries, utilizing a novel ICG fluorescence spectroscopy system for precise tumor localization. Materials and Methods: ICG should be dissolved in the provided solution or distilled water and administered intravenously approximately 24 h before surgery, beginning with an initial dose of 0.5 mg/kg. If the tumor detection rate is insufficient, the dose may be gradually increased to a maximum of 5.0 mg/kg to determine the optimal dosage for effective tumor detection. This fluorescence spectroscopy during surgery may reveal additional lesions that remain undetected in preoperative assessments. The primary endpoint includes the correct diagnostic rate of tumor localization. The secondary endpoints include the measurement of the intraoperative ICG fluorescence spectral intensity in lung tumors, the assessment of the operability and safety of intraperitoneal ICG administrations, the measurement of the ICG fluorescence spectral intensity in surgical specimens, the comparison of the spectral intensity in lung tissues during collapse and expansion, the correlation between ICG camera images and fluorescence spectral intensity, and the comparison of fluorescence analysis results with histopathological findings. The trial has been registered in the jRCT Clinical Trials Registry under the code jRCTs011230037. Results and Conclusions: This trial aims to establish an effective methodology for localizing and diagnosing malignant lung tumors, thereby potentially improving surgical outcomes and refining treatment protocols.
• A simple and safe surgical technique for nonpalpable lung tumors: One-stop Solution for a nonpalpable lung tumor, Marking, Resection, and Confirmation of the surgical margin in a Hybrid operating room (OS-MRCH).

  Aki Fujiwara-Kuroda, Masato Aragaki, Yasuhiro Hida, Hideki Ujiie, Kazuto Ohtaka, Haruhiko Shiiya, Kichizo Kaga, Tatsuya Kato

  Translational lung cancer research 13 (3) 603 - 611 2024/03/29 

  When performing thoracoscopic partial resections of nonpalpable lung tumors such as ground-glass opacities (GGOs) and small tumors, detecting the location of the lesion and assessing the resection margins can be challenging. We have developed a novel method to ease this difficulty, the One-stop Solution for a nonpalpable lung tumor, Marking, Resection, and Confirmation of the surgical margin in a Hybrid operating room (OS-MRCH), which uses a hybrid operating room wherein the operating table is seamlessly integrated with cone-beam computed tomography (CBCT). We performed the OS-MRCH method on 62 nodules including primary lung cancer presenting with GGO. Identification of the lesion and confirmation of the margin were performed in 58 of the cases, while nodules were detected in all. The frequency of computed tomography (CT) scans performed prior to resection was one time in 51 cases, two times in eight cases, and ≥3 times in three cases. Additional resection was performed in two cases. The median operative time was 85.0 minutes, and the median pathological margin was 11.0 mm. The key advantages of this method are that all surgical processes can be completed in a single session, specialized skill sets are not required, and it is feasible to perform in any facility equipped with a hybrid operating room. To overcome its disadvantages, such as longer operating time and limited patient positioning, we devised various methods for positioning patients and for CT imaging of the resected specimens. OS-MRCH is a simple, useful, and practical method for performing thoracoscopic partial resection of nonpalpable lung tumors.
• Assessment of effectiveness and safety of thrombolytic therapy to pulmonary emboli by endobronchial ultrasound-guided transbronchial needle injection.

  Yuki Sata, Masato Aragaki, Terunaga Inage, Nicholas Bernards, Alexander Gregor, Shinsuke Kitazawa, Fumi Yokote, Takamasa Koga, Hiroyuki Ogawa, Yoshihisa Hiraishi, Tsukasa Ishiwata, Andrew Effat, Kate Kazlovich, Harley Chan, Ichiro Yoshino, Kazuhiro Yasufuku

  JTCVS techniques 22 292 - 304 2023/12 [Refereed]
   

  OBJECTIVE: Endobronchial ultrasound-guided transbronchial needle injection (EBUS-TBNI) may effectively treat acute pulmonary embolisms (PEs). Here, we assessed the effectiveness of clot dissolution and safety of tissue plasminogen activator (t-PA) injection using EBUS-TBNI in a 1-week survival study of a porcine PE model. METHODS: Six pigs with bilateral PEs were used: 3 for t-PA injection using EBUS-TBNI (TBNI group) and 3 for systemic administration of t-PA (systemic group). Once bilateral PEs were created, each 25 mg of t-PA injection using EBUS-TBNI for bilateral PEs (a total of 50 mg t-PA) and 100 mg of t-PA systemic administration was performed on day 1. Hemodynamic parameters, blood tests, and contrast-enhanced computed tomography scans were carried out at several time points. On day 7, pigs were humanely killed to evaluate the residual clot volume in the pulmonary arteries. RESULTS: The average of percent change of residual clot volumes was significantly lower in the TBNI group than in the systemic group (%: systemic group 36.6 ± 22.6 vs TBNI group 9.6 ± 6.1, P < .01) on day 3. Considering the elapsed time, the average decrease of clot volume per hour at pre-t-PA to post t-PA was significantly greater in the TBNI group than in the systemic group (mm3/hour: systemic 68.1 ± 68.1 vs TBNI 256.8 ± 148.1, P < .05). No hemorrhage was observed intracranially, intrathoracically, or intraperitoneally on any contrast-enhanced computed tomography images. CONCLUSIONS: This study revealed that t-PA injection using EBUS-TBNI is an effective and safe way to dissolve clots.
• 薄壁空洞性病変を呈した原発性肺扁平上皮内癌の1例

  佐々木 明洋, 新垣 雅人, 竹野 巨樹, 山崎 洋, 野村 俊介, 大高 和人, 藤原 晶, 氏家 秀樹, 榊原 純, 大川 紘弥, 松野 吉宏, 加藤 達哉

  気管支学 (一社)日本呼吸器内視鏡学会 45 (6) 443 - 443 0287-2137 2023/11
• 後期高齢者に対する脳死肺移植の2例

  稲毛 輝長, 新垣 雅人, バー・ジェームス, 鈴木 秀海, 吉野 一郎, マルセロ・サイペル

  日本胸部外科学会定期学術集会 (一社)日本胸部外科学会 76回 LOP2 - 4 2023/10
• 後期高齢者に対する脳死肺移植の2例

  稲毛 輝長, 新垣 雅人, バー・ジェームス, 鈴木 秀海, 吉野 一郎, マルセロ・サイペル

  日本胸部外科学会定期学術集会 (一社)日本胸部外科学会 76回 LOP2 - 4 2023/10
• Identification of micro-recurrent lesions using methylene blue for mediastinal ectopic parathyroid adenoma: a case report(タイトル和訳中)

  Nomura Shunsuke, Ujiie Hideki, Fujiwara-Kuroda Aki, Kaga Kichizo, Aragaki Masato, Muto Jun, Chiba Ryohei, Yamazaki Gaku, Wakabayashi Kento, Matsuno Yoshihiro, Kato Tatsuya

  General Thoracic and Cardiovascular Surgery Cases 2 1 of 4 - 4 of 4 2023/08
• 肺胞出血を合併したLymphangioleiomyomatosisの1例

  大高 和人, 竹野 巨樹, 山崎 洋, 佐々木 明洋, 野村 俊介, 藤原 晶, 氏家 秀樹, 新垣 雅人, 加藤 達哉, 武井 望, 小熊 昂, 今野 哲, 大川 紘弥, 松野 吉宏

  日本気胸・嚢胞性肺疾患学会雑誌 日本気胸・嚢胞性肺疾患学会 23 (2) 90 - 90 1883-0412 2023/08
• 肺胞出血を合併したLymphangioleiomyomatosisの1例

  大高 和人, 竹野 巨樹, 山崎 洋, 佐々木 明洋, 野村 俊介, 藤原 晶, 氏家 秀樹, 新垣 雅人, 加藤 達哉, 武井 望, 小熊 昂, 今野 哲, 大川 紘弥, 松野 吉宏

  日本気胸・嚢胞性肺疾患学会雑誌 日本気胸・嚢胞性肺疾患学会 23 (2) 90 - 90 1883-0412 2023/08
• 気管支3Dモデルを用いた手術シミュレーション

  藤原 晶, 山崎 雅久, 千葉 龍平, 野村 俊介, 武藤 潤, 氏家 秀樹, 新垣 雅人, 加賀 基知三, 道田 共博, 若林 侑輝, 佐伯 和紀, 山口 仰, 加藤 達哉

  日本呼吸器外科学会雑誌 (一社)日本呼吸器外科学会 37 (3) O39 - 6 0919-0945 2023/06
• 術後経時的ctDNA測定と腫瘍マーカーを併用した肺癌術後フォローアップ法は再発検出率を向上させる

  加藤 達哉, Ming Chin Yoon, Low Siew-Kee, 清谷 一馬, 氏家 秀樹, 藤原 晶, 新垣 雅人, 中村 祐輔

  日本呼吸器外科学会雑誌 (一社)日本呼吸器外科学会 37 (3) O52 - 3 0919-0945 2023/06
• 術前、術後免疫チェックポイント阻害薬および肺剥皮術による集学的治療を行ったびまん性胸膜中皮腫の1例

  山崎 雅久, 藤原 晶, 千葉 龍平, 野村 俊介, 武藤 潤, 氏家 秀樹, 新垣 雅人, 加賀 基知三, 古田 恵, 大野 桜子, 松野 吉宏, 加藤 達哉

  日本呼吸器外科学会雑誌 (一社)日本呼吸器外科学会 37 (3) O59 - 2 0919-0945 2023/06
• 左上葉切除後の脳梗塞発症予防として肺静脈心嚢内処理を施行した症例の検討

  武藤 潤, 山崎 雅久, 千葉 龍平, 野村 俊介, 藤原 晶, 氏家 秀樹, 新垣 雅人, 加賀 基知三, 加藤 達哉

  日本呼吸器外科学会雑誌 (一社)日本呼吸器外科学会 37 (3) O73 - 5 0919-0945 2023/06
• 巨大ダンベル型脊髄腫瘍に対する、後方アプローチおよびロボット支援下手術(RATS)

  氏家 秀樹, 中谷 匠, 山崎 雅久, 野村 俊介, 千葉 龍平, 武藤 潤, 藤原 晶, 新垣 雅人, 加賀 基知三, 高畑 雅彦, 松野 吉宏, 加藤 達哉

  日本呼吸器外科学会雑誌 (一社)日本呼吸器外科学会 37 (3) P42 - 1 0919-0945 2023/06
• 多発胸腺腫疑いに対し手術を施行し、胸腺癌と胸腺腫の同時多発が判明した1例

  中谷 匠, 野村 俊介, 藤原 晶, 氏家 秀樹, 新垣 雅人, 加賀 基知三, 加藤 憲士郎, 松野 吉宏, 加藤 達哉

  日本呼吸器外科学会雑誌 (一社)日本呼吸器外科学会 37 (3) P68 - 7 0919-0945 2023/06
• 10℃保存により24時間の全肺虚血時間においても良好な経過をとった両側肺葉移植の一例

  新垣 雅人, 稲毛 輝長, 川島 光明, 谷口 大輔, 石綿 司, 加藤 達哉, 安福 和弘, Keshavjee Shaf, Cypel Marcelo

  移植 (一社)日本移植学会 57 (4) 396 - 396 0578-7947 2023/04
• 医学生、研修医を対象とした医学教育とメディカルイラストの利用

  加賀 基知三, 藤原 晶, 山崎 雅久, 千葉 龍平, 野村 俊介, 武藤 潤, 氏家 秀樹, 新垣 雅人, 加藤 達哉

  日本メディカルイラストレーション学会学術集会・総会 日本メディカルイラストレーション学会 7回 O - 3 2023/03
• Preclinical feasibility of bronchoscopic fluorescence-guided lung sentinel lymph node mapping.

  Alexander Gregor, Yuki Sata, Yoshihisa Hiraishi, Tsukasa Ishiwata, Masato Aragaki, Shinsuke Kitazawa, Takamasa Koga, Hiroyuki Ogawa, Nicholas Bernards, Kazuhiro Yasufuku

  The Journal of thoracic and cardiovascular surgery 165 (1) 337 - 350 2023/01 [Refereed]
   

  OBJECTIVE: Lung sentinel lymph node mapping, where peritumorally injected material is tracked through the lymphatics, aims to find the first potential sites of nodal metastasis. We sought to evaluate the preclinical feasibility of bronchoscopic fluorescence-guided sentinel lymph node mapping. METHODS: Healthy Yorkshire pigs were used; sentinel lymph node mapping was performed with indocyanine green. The primary fluorescence imaging method was an ultrathin composite fiberscope placed in the bronchoscope working channel. Secondary methods used a fluorescence thoracoscope placed in the trachea (rigid bronchoscopy) and pretracheal fascial plane (mediastinoscopy) to validate ultrathin composite fiberscope settings for sentinel lymph node detection. A tracheostomy was created, and the pig was placed in a lateral decubitus position. Transbronchial intraparenchymal indocyanine green injection was performed primarily in the right lower lobe. Ultrathin composite fiberscope and rigid bronchoscopy were performed with (n = 6) or without (n = 2) mediastinoscopy, with the former group guiding dose and ultrathin composite fiberscope optimization. Fluorescent targets were interrogated by endobronchial ultrasound before ultrathin composite fiberscope-guided transbronchial needle aspiration. Specimen fluorescence was documented before creating cytological smears. Pigs were killed postprocedure for nodal dissection. RESULTS: A total of 100 μL of 10 mg/mL indocyanine green generated strong transbronchial fluorescence with low risk of indocyanine green contamination. Fluorescence was detectable by 10 minutes postinjection. There was concordance among ultrathin composite fiberscope, rigid bronchoscopy, and mediastinoscopy. Except for 1 pig with airway contamination, ultrathin composite fiberscope-guided endobronchial ultrasound transbronchial needle aspiration obtained fluorescent material in all pigs. Specimen fluorescence was associated with specimen adequacy. CONCLUSIONS: Bronchoscopic fluorescence-guided sentinel lymph node mapping was feasible, with specimen fluorescence providing real-time feedback on sentinel lymph node biopsy success. If translated to clinical practice, attention must be paid to minimizing indocyanine green leakage.
• Repeated photodynamic therapy mediates the abscopal effect through multiple innate and adaptive immune responses with and without immune checkpoint therapy.

  Jenny Lou, Masato Aragaki, Nicholas Bernards, Tess Chee, Alexander Gregor, Yoshihisa Hiraishi, Tsukasa Ishiwata, Chelsea Leung, Lili Ding, Shinsuke Kitazawa, Takamasa Koga, Yuki Sata, Hiroyuki Ogawa, Juan Chen, Tatsuya Kato, Kazuhiro Yasufuku, Gang Zheng

  Biomaterials 292 121918 - 121918 2023/01 [Refereed]
   

  In combination with immune checkpoint inhibitors, photodynamic therapy can induce robust immune responses capable of preventing local tumor recurrence and delaying the growth of distant, untreated disease (ie. the abscopal effect). Previously, we found that repeated photodynamic therapy (R-PDT) using porphyrin lipoprotein (PLP) as a photosensitizer, without the addition of an immune checkpoint inhibitor, can induce the abscopal effect. To understand why PLP mediated R-PDT alone can induce the abscopal effect, and how the addition of an immune checkpoint inhibitor can further strengthen the abscopal effect, we investigated the broader immune mechanisms facilitated by R-PDT and combination R-PDT + anti-PD-1 monoclonal antibody (αPD-1) in a highly aggressive, subcutaneous AE17-OVA mesothelioma dual tumor-bearing C57BL/6 mice. We found a 46.64-fold and 61.33-fold increase in interleukin-6 (IL-6) after R-PDT and combination R-PDT + αPD-1 relative to PBS respectively, suggesting broad innate immune activation. There was a greater propensity for antigen presentation in the spleen and distal, non-irradiated tumor draining lymph nodes, as dendritic cells and macrophages had increased expression of MHC class II, CD80, and CD86, after R-PDT and combination R-PDT + αPD-1. Concurrently, there was a shift in the proportions of CD4+ T cell subsets in the spleen, and an increase in the frequency of CD8+ T cells in the distal, non-irradiated tumor draining lymph nodes. While R-PDT had an acceptable safety profile, combination R-PDT + αPD-1 induced 1.26-fold higher serum potassium and 1.33-fold phosphorus, suggestive of mild laboratory tumor lysis syndrome. Histology revealed an absence of gross inflammation in critical organs after R-PDT and combination R-PDT + αPD-1 relative to PBS-treated mice. Taken together, our findings shed light on how the abscopal effect can be induced by PDT and strengthened by combination R-PDT + αPD-1, and suggests minimal toxicities after R-PDT.
• Non-Perfused Organ Donorによる肺移植の1例

  稲毛 輝長, 新垣 雅人, 川島 光明, オリ・ハーバーフェルド, 吉野 一郎, シャフ・ケシャブジー

  日本胸部外科学会定期学術集会 (一社)日本胸部外科学会 75回 LP9 - 1 2022/10
• Transbronchial real-time lung tumor localization with folate receptor-targeted near-infrared molecular imaging: A proof of concept study in animal models.

  Tsukasa Ishiwata, Yoshihisa Hiraishi, Nicholas Bernards, Yuki Sata, Alexander Gregor, Masato Aragaki, Kazuhiro Yasufuku

  The Journal of thoracic and cardiovascular surgery 2022/09/28 [Refereed]
   

  OBJECTIVE: The diagnostic yield of bronchoscopy is not satisfactory, even with recent navigation technologies, especially for tumors located outside of the bronchial lumen. Our objective was to perform a preclinical assessment of folate receptor-targeted near-infrared imaging-guided bronchoscopy to detect peribronchial tumors. METHODS: Pafolacianine, a folate receptor-targeted molecular imaging agent, was used as a near-infrared fluorescent imaging agent. An ultra-thin composite optical fiberscope was used for laser irradiation and fluorescence imaging. Subcutaneous xenografts of KB cells in mice were used as folate receptor-positive tumors. Tumor-to-background ratio was calculated by the fluorescence intensity value of muscle tissues acquired by the ultra-thin composite optical fiberscope system and validated using a separate spectral imaging system. Ex vivo swine lungs into which pafolacianine-laden KB tumors were transplanted at various sites were used as a peribronchial tumor model. RESULTS: With the in vivo murine model, tumor-to-background ratio observed by ultra-thin composite optical fiberscope peaked at 24 hours after pafolacianine injection (tumor-to-background ratio: 2.56 at 0.05 mg/kg, 2.03 at 0.025 mg/kg). The fluorescence intensity ratios between KB tumors and normal mouse lung parenchyma postmortem were 6.09 at 0.05 mg/kg and 5.08 at 0.025 mg/kg. In the peribronchial tumor model, the ultra-thin composite optical fiberscope system could successfully detect fluorescence from pafolacianine-laden folate receptor-positive tumors with 0.05 mg/kg at the carina and those with 0.025 mg/kg and 0.05 mg/kg in the peripheral airway. CONCLUSIONS: Transbronchial detection of pafolacianine-laden folate receptor-positive tumors by near-infrared imaging was feasible in ex vivo swine lungs. Further in vivo preclinical assessment is needed to confirm the feasibility of this technology.
• Optimization of thrombolytic dose for treatment of pulmonary emboli using endobronchial ultrasound-guided transbronchial needle injection.

  Masato Aragaki, Terunaga Inage, Tsukasa Ishiwata, Alexander Gregor, Nicholas Bernards, Tatsuya Kato, Kazuhiro Yasufuku

  The Journal of thoracic and cardiovascular surgery 165 (5) e210-e221  2022/09/14 [Refereed]
   

  OBJECTIVE: Severe pulmonary embolism is often managed with thrombolysis. We sought to determine whether endobronchial ultrasound (EBUS)-guided transbronchial thrombolysis remained effective at lower alteplase doses, with the goal of minimizing potential bleeding risk. METHODS: Yorkshire pigs were anesthetized and ventilated. Preformed autologous blood clots were administered into bilateral pulmonary arteries via EBUS-guided transbronchial injection. After documenting baseline clot sizes, alteplase was injected into the clots using a 25-gauge transbronchial needle and clot dissolution was monitored over 30 minutes. The study was performed in 2 phases. First, alteplase doses of 5 and 12.5 mg were evaluated. These results informed dose selection for the second phase. Results were compared with 25-mg dose data using EBUS from a previous study. RESULTS: In the first phase, 3 clots were evaluated. Distilled water, 5 mg, and 12.5 mg alteplase were administered. The dissolved clot volume (Vdis) and percentage clot volume loss (Rdis) were -10.9, 111.6, and 160.3 mm3, and -1.6%, 11.0%, and 59.3%, respectively. In the second phase, alteplase doses of 5, 10, and 15 mg were evaluated in 12 clots across 6 pigs. The Vdis were 247.5 mm3 (Rdis, 20.1%), 910.8 mm3 (Rdis, 80.9%), and 798.3 mm3 (Rdis, 76.0%) for 5, 10, and 15 mg alteplase, respectively. Remakably reduced performance was observed with 5 mg alteplase versus 10 mg (Vdis: P < .001, Rdis: P < .001), and 15 mg (Vdis: P = .004; Rdis: P < .001). No complications were observed. CONCLUSIONS: Alteplase doses ≥10 mg were optimal for EBUS-guided transbronchial thrombolysis. This technique might represent an effective alternative therapy for central pulmonary embolism.
• Preclinical evaluation of thin convex probe endobronchial ultrasound-guided transbronchial needle aspiration for intrapulmonary lesions.

  Tsukasa Ishiwata, Terunaga Inage, Alexander Gregor, Yamato Motooka, Harley H L Chan, Nicholas Bernards, Masato Aragaki, Zhenchian Chen, Hideki Ujiie, Tomonari Kinoshita, Andrew Effat, Kazuhiro Yasufuku

  Translational lung cancer research 11 (7) 1292 - 1301 2022/07 [Refereed]
   

  Background: Conventional flexible bronchoscopy has not achieved the high diagnostic yield for intrapulmonary lesions as seen with image-guided transthoracic biopsy. A thin convex probe endobronchial ultrasound bronchoscope (TCP-EBUS) with a 5.9-mm tip was designed to improve peripheral access over conventional EBUS bronchoscopes to facilitate real-time sampling of intrapulmonary lesions under ultrasound guidance. Methods: TCP-EBUS was inserted into the distal airways of ex-vivo human lungs to assess bronchial accessibility relative to clinically available bronchoscopes. The short- (≤1 h) and medium-term (≤10 d) safety of TCP-EBUS insertion and EBUS-guided transbronchial needle aspiration (TBNA) using a 25-gauge needle were evaluated physiologically and radiologically in live pigs. TCP-EBUS-guided TBNA feasibility was assessed in-vivo with pig intrapulmonary pseudo-tumors and ex-vivo with resected human lung cancer specimens. Results: For bronchial accessibility, TCP-EBUS demonstrated greater reach than the 6.6-mm convex probe endobronchial ultrasound (CP-EBUS) in all bronchi, as well as surpassed a 5.5-mm conventional bronchoscope in 63% (131/209) and a 4.8-mm conventional bronchoscope in 27% (57/209) of assessed bronchi. The median bronchial generation and the mean diameter of bronchi TCP-EBUS reached was 4 (range, 3-7) and 3.3±0.7 mm, respectively. No major complications related to TCP-EBUS-guided TBNA in distal airways were observed in the live pigs. Scattered mucosal erythema of the bronchial walls was observed immediately after TCP-EBUS insertion; this self-resolved by day 10. TCP-EBUS could successfully reach and visualize intrapulmonary targets via ultrasound, with no difficulty in needle deployment or sampling. Conclusions: TCP-EBUS has the potential to facilitate safe real-time transbronchial sampling of intrapulmonary lesions in the central and middle lung fields.
• Endobronchial ultrasound-guided bipolar radiofrequency ablation for lung cancer: A first-in-human clinical trial.

  Tsukasa Ishiwata, Yamato Motooka, Hideki Ujiie, Terunaga Inage, Alexander Gregor, Masato Aragaki, Zhenchian Chen, Tomonari Kinoshita, Laura Donahoe, Jonathan Yeung, Marcelo Cypel, Marc de Perrot, Andrew Pierre, Gail Darling, Thomas Waddell, Shaf Keshavjee, Prodipto Pal, Kazuhiro Yasufuku

  The Journal of thoracic and cardiovascular surgery 2022/03/26 [Refereed]
   

  OBJECTIVE: Percutaneous radiofrequency ablation (RFA) is a therapeutic option for lung tumors. However, percutaneous approaches have limited access to central lung regions and a relatively high complication rate. To overcome these limitations, a needle-type bipolar RFA device compatible with an endobronchial ultrasound (EBUS) bronchoscope was developed. The aim of this pilot study was to evaluate the immediate-term safety and ablation zone of lung tumor EBUS-guided RFA. METHODS: This was an ablate-and-resect study in patients scheduled for surgical resection of clinical stage I or II lung cancer or metastatic lung lesions ≥1 cm that were accessible using an EBUS bronchoscope. The RFA electrodes were placed within the lung nodule using EBUS guidance followed by ablation. Bronchoscopy and contrast-enhanced computed tomography were performed to evaluate for post-RFA complications. The resected lung underwent pathological assessment to characterize the ablation zone. RESULTS: A total of 5 primary lung cancers were ablated in 5 separate patients; no patients with metastatic lesions were recruited. For a total energy of 4 kJ (n = 3), 6 kJ (n = 1), and 8 kJ (n = 1) delivered, the ablation time was a mean of 13.8 (range, 10.3-16.0) minutes, 8.4 minutes, and 15.6 minutes, respectively, and the maximum ablation diameter was a mean of 1.8 (range, 1.3-2.1) cm, 2.7 cm, and 2.6 cm, respectively. No immediate post-RFA complications were observed. CONCLUSIONS: EBUS-guided bipolar RFA can ablate lung tumors using real-time ultrasound guidance. EBUS-guided RFA might ultimately represent a minimally invasive therapy for lung cancer in patients unable to tolerate surgery. Longer-term safety will need to be evaluated.
• Development of a minimally invasive pulmonary porcine embolism model via endobronchial ultrasound.

  Terunaga Inage, Kosuke Fujino, Yamato Motooka, Tsukasa Ishiwata, Hideki Ujiie, Alexander Gregor, Nicholas Bernards, Harley H L Chan, Zhenchian Chen, Masato Aragaki, Tomonari Kinoshita, Andrew Effat, Ichiro Yoshino, Kazuhiro Yasufuku

  Journal of thoracic disease 14 (2) 238 - 246 2022/02 [Refereed]
   

  Background: Current massive pulmonary embolism (PE) animal models use central venous access to deliver blood clots, which have features of random clot distribution and potentially fatal hemodynamic compromise. A clinically relevant preclinical model for generating pulmonary emboli in a more controlled fashion would be of value for a variety of research studies, including initial evaluation of novel therapeutic approaches. Endobronchial ultrasound-guided transbronchial needle injection (EBUS-TBNI) is a newly established approach for peri-tracheal/bronchial targets. The purpose of the present work was to establish a minimally invasive PE model in swine via a transbronchial approach. Methods: In anesthetized Yorkshire pigs, a 21-G EBUS-guided transbronchial needle aspiration (EBUS-TBNA) needle was introduced into the pulmonary artery under EBUS guidance. Autologous blood clots were administered into the right and left lower pulmonary arteries sequentially (PE1 and PE2, respectively). Hemodynamic and biochemical responses were evaluated. Results: Ten pigs were evaluated; all 20 blood clots (6.3±1.9 mL) were successfully injected. After injection, mean pulmonary artery pressure (mPAP; mmHg) increased (baseline: 16.6±5.6 vs. PE1: 24.5±7.6, P<0.0001 vs. PE2: 26.9±6.7, P<0.0001), and a positive correlation was observed between clot volume and change in mPAP (PE1: r=0.69, P=0.025; PE1 + PE2: r=0.60, P=0.063). Mean arterial pressure (MAP; mmHg) (baseline: 57.5±5.1 vs. PE1: 59.0±9.1, P=0.918 vs. PE2: 60.9±9.6, P=0.664) remained stable. No complications were observed. Conclusions: EBUS allows minimally invasive, precise, and reliable generation of pulmonary emboli in pigs. This model may serve as an important tool for new PE-related diagnostic and therapeutic research.
• Intralobar pulmonary sequestration associated with left main coronary artery obstruction and mitral regurgitation.

  Yusuke Motohashi, Tatsuya Kato, Nobuyasu Kato, Masato Aragaki, Aki Fujiwara-Kuroda, Tsuyoshi Tachibana, Yasuhiro Hida, Kichizo Kaga, Satoru Wakasa

  General thoracic and cardiovascular surgery 69 (12) 1575 - 1579 2021/09/21 [Refereed]
   

  A 4-year-old boy with left intralobar pulmonary sequestration associated with left main coronary artery obstruction (LMCAO) and severe mitral regurgitation (MR) was admitted to our hospital. Since the patient presented with dyskinesia of the cardiac apex and increased left ventricular end-diastolic volume (LVEDV), left main coronary artery reconstruction and mitral annuloplasty were performed. The enlargement of the left ventricle was improved after sequential surgeries. There was a risk of deterioration of MR and regrowth of LVEDV due to shunt blood flow; therefore, left lower lobectomy and aberrant artery division were performed. This is a very rare case of a patient with pulmonary sequestration associated with LMCAO and severe MR.
• Repeated porphyrin lipoprotein-based photodynamic therapy controls distant disease in mouse mesothelioma via the abscopal effect

  Jenny Lou, Masato Aragaki, Nicholas Bernards, Tomonari Kinoshita, Jessica Mo, Yamoto Motooka, Tsukasa Ishiwata, Alexander Gregor, Tess Chee, Zhenchian Chen, Juan Chen, Kichizo Kaga, Satoru Wakasa, Gang Zheng, Kazuhiro Yasufuku

  NANOPHOTONICS 10 (12) 3279 - 3294 2192-8606 2021/09 [Refereed]
   

  While photodynamic therapy (PDT) can induce acute inflammation in the irradiated tumor site, a sustained systemic, adaptive immune response is desirable, as it may control the growth of nonirradiated distant disease. Previously, we developed porphyrin lipoprotein (PLP), a similar to 20 nm nanoparticle photosensitizer, and observed that it not only efficiently eradicated irradiated primary VX2 buccal carcinomas in rabbits, but also induced regression of nonirradiated metastases in a draining lymph node. We hypothesized that PLP-mediated PDT can induce an abscopal effect and we sought to investigate the immune mechanism underlying such a response in a highly aggressive, dual subcutaneous AE17-OVA+ mesothelioma model in C57BL/6 mice. Four cycles of PLP-mediated PDT was sufficient to delay the growth of a distal, nonirradiated tumor four-fold relative to controls. Serum cytokine analysis revealed high interleukin-6 levels, showing a 30-fold increase relative to phosphate-buffered solution (PBS) treated mice. Flow cytometry revealed an increase in CD4+ T cells and effector memory CD8+ T cells in non-irradiated tumors. Notably, PDT in combination with PD-1 antibody therapy prolonged survival compared to monotherapy and PBS. PLP-mediated PDT shows promise in generating a systemic immune response that can complement other treatments, improving prognoses for patients with metastatic cancers.
• Thrombolysis of Pulmonary Emboli via Endobronchial Ultrasound-Guided Transbronchial Needle Injection.

  Terunaga Inage, Kosuke Fujino, Yamato Motooka, Tsukasa Ishiwata, Hideki Ujiie, Nicholas Bernards, Alexander Gregor, Zhenchian Chen, Masato Aragaki, Tomonari Kinoshita, Ichiro Yoshino, Kazuhiro Yasufuku

  The Annals of thoracic surgery 112 (2) 395 - 404 2021/08 [Refereed]
   

  BACKGROUND: Endobronchial ultrasound-guided transbronchial needle injection (EBUS-TBNI) is a novel technique for treating peribronchial targets. The aim of this study was to evaluate preliminary feasibility of thrombolysis of pulmonary emboli via EBUS-TBNI. METHODS: Yorkshire pigs (30-48 kg) were anesthetized and mechanically ventilated. Pre-formed autologous clots were injected sequentially into bilateral lower pulmonary arteries in bilateral models (PE1 and PE2, respectively) or into 1 side in unilateral models using a 21-gauge EBUS-TBNA needle under EBUS guidance. In the bilateral model, 2 hours after clot injection either 25 mL of tissue-plasminogen activator (t-PA; 1mg/mL) or distilled water were administered into each embolus via 25-gauge EBUS-TBNA needle. In the unilateral model, 25 mg t-PA was administered intravenously. Hemodynamic parameters were monitored continuously, and clot dissolved volume was evaluated by EBUS 30 minutes post-treatment administration. RESULTS: All clots (6.1 ± 1.7 mL) were successfully injected as documented by EBUS Doppler imaging. Clot injection in the bilateral model (n = 6) increased pulmonary arterial pressure (mm Hg: Baseline 19.2 ± 5.9 vs PE1: 26.7 ± 9.1, P = .005 vs PE2 29.9 ± 7.1, P = .0007). After t-PA TBNI in the bilateral model (n = 6), pulmonary arterial pressure at 30 minutes post-injection showed improvement (mm Hg: PE2 29.9 ± 7.1 vs post-t-PA 24.4 ± 3.9, P = .0283). Treatment with t-PA TBNI demonstrated superior clot dissolution at 30 minutes post-treatment (dissolved mm3: t-PA TBNI 625.4 ± 156.6 vs t-PA intravenously: 181.6 ± 94.3, P = .0003 vs distilled water TBNI 42.5 ± 33.0, P < .0001). There were no complications. CONCLUSIONS: EBUS-guided transbronchial thrombolysis may be a feasible approach for treating central pulmonary emboli.
• Pilot study using virtual 4-D tracking electromagnetic navigation bronchoscopy in the diagnosis of pulmonary nodules: a single center prospective study

  Tsukasa Ishiwata, Hideki Ujiie, Alexander Gregor, Terunaga Inage, Yamato Motooka, Tomonari Kinoshita, Masato Aragaki, Zhenchian Chen, Andrew Effat, Nicholas Bernards, Kazuhiro Yasufuku

  Journal of Thoracic Disease 13 (5) 2885 - 2895 2072-1439 2021/05 [Refereed]
  
• Feasibility of limited resection for peripheral small-sized non-small cell lung cancer: a retrospective single-center-based study.

  Masato Aragaki, Yasuhiro Hida, Tatsuya Kato, Aki Fujiwara-Kuroda, Kichizo Kaga, Satoru Wakasa

  Journal of cancer research and clinical oncology 147 (5) 1519 - 1527 2021/05 [Refereed]
   

  PURPOSE: This study aimed to establish new criteria for limited resection of non-small cell lung cancer (NSCLC) based on computed tomography findings and maximum standardized uptake value (SUVmax). METHODS: Between December 2007 and December 2015, 611 patients underwent lung cancer surgery; of these, 70 with cT1aN0M0 who underwent limited resection were enrolled. Criteria for undergoing intentional limited resection (ILR) were (1) tumor ground-glass opacity (GGO) ratio of ≥ 0.75 and (2) tumor SUVmax ≤ 1.5. Patients who met criteria (1) and (2) underwent partial resection, and those who only met criteria (2) underwent segmentectomy as ILR. The control group was subjected to limited surgery without meeting the criteria. RESULTS: Overall, 45 and 25 patients who met the criteria were included in the ILR and control groups, respectively. In the ILR group, 13 patients underwent partial resection, and 32 underwent segmentectomy; in the control group, 18 patients underwent partial resection and 7 underwent segmentectomy. According to our criteria, no relapsed cases occurred in the ILR group, although six patients showed recurrence of lung cancer in the control group. The 5-year overall survival (OS) rates in the ILR and control groups were 100% and 67.7%, respectively, and the relapse-free survival (RFS) rates were 100% and 61.6%, respectively. The log-rank test showed that this difference was statistically significant (OS: P < 0.0001, RFS: P < 0.0001). CONCLUSIONS: SUVmax may serve as a predictive marker of recurrence to determine the treatment strategy for patients with NSCLC. Patients with low GGO ratio and low SUVmax may be cured by limited resection.
• Intraoperative real-time hemodynamics in intralobar pulmonary sequestration using indocyanine green and near-infrared thoracoscopy.

  Yusuke Motohashi, Tatsuya Kato, Masato Aragaki, Aki Fujiwara-Kuroda, Yasuhiro Hida, Satoru Wakasa, Kichizo Kaga

  General thoracic and cardiovascular surgery 69 (2) 383 - 387 2021/02 [Refereed]
   

  A 33-year-old man with left pulmonary sequestration was admitted to our hospital. We planned left basilar segmentectomy to preserve the lung function, using indocyanine green (ICG) and near-infrared thoracoscopy. The intravenous (IV) administration of ICG (0.1 mg/kg) showed the distribution of fluorescence from the aberrant arteries, blood flow blockage from the aberrant arteries after they were divided, and the superior-basal boundary after the pulmonary artery and vein were divided. In adult patients with intralobar pulmonary sequestration, ICG and near-infrared thoracoscopic techniques are useful to confirm abnormal hemodynamics and demonstrate a safe and successful basilar segmentectomy.
• A preclinical research platform to evaluate photosensitizers for transbronchial localization and phototherapy of lung cancer using an orthotopic mouse model.

  Tsukasa Ishiwata, Takeshi Seki, Alexander Gregor, Masato Aragaki, Yamato Motooka, Tomonari Kinoshita, Terunaga Inage, Nicholas Bernards, Hideki Ujiie, Zhenchian Chen, Andrew Effat, Juan Chen, Gang Zheng, Koichiro Tatsumi, Kazuhiro Yasufuku

  Translational lung cancer research 10 (1) 243 - 251 2021/01 [Refereed]
   

  Background: Establishing the efficacy of novel photosensitizers (PSs) for phototherapy of lung cancer requires in vivo study prior to clinical evaluation. However, previously described animal models are not ideal for assessing transbronchial approaches with such PSs. Methods: An ultra-small parallel-type composite optical fiberscope (COF) with a 0.97 mm outer diameter tip. The integration of illumination and laser irradiation fibers inside the COF allows simultaneous white-light and fluorescence imaging, as well as real-time monitoring of tip position during laser phototherapy. An orthotopic lung cancer mouse model was created with three human lung cancer cell lines transbronchially inoculated into athymic nude mice. The COF was inserted transbronchially into a total of 15 mice for tumor observation. For in vivo fluorescence imaging, an organic nanoparticle, porphysome, was used as a PS. Laser excitation through the COF was performed at 50 mW using a 671 nm source. Results: The overall success rate for creating orthotopic lung tumors was 71%. Transbronchial white light images were successfully captured by COF. Access to the left main bronchus was successful in 87% of mice (13/15), the right main bronchus to the cranial lobe bronchus level in 100% (15/15), and to the right basal trifurcation of the middle lobe, caudal lobe and accessory lobe in 93% (14/15). For transbronchial tumor localization of orthotopic lung cancer tumors, PS-laden tumor with the strong signal was clearly contrasted from the normal bronchial wall. Conclusions: The ultra-small COF enabled reliable transbronchial access to orthotopic human lung cancer xenografts in vivo. This method could serve as a versatile preclinical research platform for PS evaluation in lung cancer, enabling transbronchial approaches in in vivo survival models inoculated with human lung cancer cells.
• 肺移植患者における超音波気管支鏡の安全性および有効性の検討

  氏家 秀樹, 加藤 達哉, 稲毛 輝長, 石綿 司, 新垣 雅人, 樋田 泰浩, 加賀 基知三, 若狭 哲, Keshavjee Shaf, Yasufuku Kazuhiro

  移植 (一社)日本移植学会 55 (総会臨時) 383 - 383 0578-7947 2020/10
• Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study.

  Masato Aragaki, Tatsuya Kato, Aki Fujiwara-Kuroda, Yasuhiro Hida, Kichizo Kaga, Satoru Wakasa

  Journal of cardiothoracic surgery 15 (1) 229 - 229 2020/08/28 [Refereed]
   

  BACKGROUND: Given the difficulty in preoperatively diagnosing lymph node metastasis, patients with Stage I-III non-small cell lung cancer (NSCLC) are likely to be included in the clinical N1 (cN1) group. However, better treatment options might be selected through further stratification. This study aimed to identify preoperative clinicopathological prognostic and stratification factors for patients with cN1 NSCLC. METHODS: This retrospective study evaluated 60 patients who were diagnosed with NSCLC during 2004-2014. Clinical nodal status had been evaluated using routine chest computed tomography (CT) and/or positron emission tomography (PET). To avoid biasing the fluorodeoxyglucose uptake values based on inter-institution or inter-model differences, we used only two PET systems (one PET system and one PET/CT system). Relapse-free survival (RFS) and overall survival (OS) were the primary study outcomes. The maximum standardized uptake value (SUVmax) was calculated for each tumor and categorized as low or high based on the median value. Patient sex, age, histology, tumor size, and tumor markers were also assessed. RESULTS: Poor OS was associated with older age (P = 0.0159) and high SUVmax values (P = 0.0142). Poor RFS was associated with positive carcinoembryonic antigen (CEA) expression (P = 0.0035) and high SUVmax values (P = 0.015). Multivariate analyses confirmed that poor OS was independently predicted by older age (hazard ratio [HR] = 2.751, confidence interval [CI]: 1.300-5.822; P = 0.0081) and high SUVmax values (HR = 5.121, 95% CI: 1.759-14.910; P = 0.0027). Furthermore, poor RFS was independently predicted by positive CEA expression (HR = 2.376, 95% CI: 1.056-5.348; P = 0.0366) and high SUVmax values (HR = 2.789, 95% CI: 1.042-7.458; P = 0.0410). The primary tumor's SUVmax value was also an independent prognostic factor for both OS and RFS. CONCLUSIONS: For patients with cN1 NSCLC, preoperative prognosis and stratification might be performed based on CEA expression, age, and the primary tumor's SUVmax value. To enhance the prognostic value of the primary tumor's SUVmax value, minimizing bias between facilities and models could lead to a more accurate prognostication.
• イメージガイド下センチネルリンパ節マッピングのためのマルチモーダルなナノスケール薬(A multi-modal nanoscale agent for image-guided sentinel lymph node mapping)

  Ujiie Hideki, Chan Harley, Gregor Alexander, Motooka Yamato, Inage Terunaga, Aragaki Masato, Kato Tatsuya, Hida Yasuhiro, Kaga Kichizo, Waddell Thomas K, Keshavjee Shaf, Yasufuku Kazuhiro

  日本呼吸器外科学会雑誌 34 (3) IS2 - 2 0919-0945 2020/08
• 超音波気管支鏡ガイド下針生検(EBUS-TBNI)を用いた肺塞栓に対するdirected thrombolysis approachの開発(Development of a directed thrombolysis approach to central pulmonary emboli using minimally invasive endobronchial ultrasound-guided transbronchial needle injection(EBUS-TBNI): A porcine pre-clinical experiment)

  Inage Terunaga, Fujino Kosuke, Motooka Yamato, Ishiwata Tsukasa, Gregor Alexander, Ujiie Hideki, Bernards Nicholas, Chen Zhenchian, Aragaki Masato, Effat Andrew, Yoshino Ichiro, Yasufuku Kazuhiro

  日本外科学会定期学術集会抄録集 120回 SF - 6:[T] 2020/08
• イメージガイド下センチネルリンパ節マッピングのためのマルチモーダルなナノスケール薬(A multi-modal nanoscale agent for image-guided sentinel lymph node mapping)

  Ujiie Hideki, Chan Harley, Gregor Alexander, Motooka Yamato, Inage Terunaga, Aragaki Masato, Kato Tatsuya, Hida Yasuhiro, Kaga Kichizo, Waddell Thomas K, Keshavjee Shaf, Yasufuku Kazuhiro

  日本呼吸器外科学会雑誌 34 (3) IS2 - 2 0919-0945 2020/08
• A Novel Insertion Technique for the Extra-Long Montgomery T-Tube in Patients with a Large Mediastinal Tumor.

  Tatsuya Kato, Aki Fujiwara-Kuroda, Nobuyuki Shiina, Masato Aragaki, Hideki Ujiie, Yasuhiro Hida, Kichizo Kaga

  Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 26 (5) 294 - 297 2020/08/01 [Refereed][Not invited]
   

  The Montgomery T-tube is widely used to stent airway stenotic diseases. Conventional insertion methods can sometimes fail in the case of long-distance subglottic stenosis due to the flexibility of a T-tube made of silicon, which kinks when forced against resistance. Therefore, an alternative approach can assist in the insertion of an extra-long T-tube, especially when using a long proximal limb. We report herein the case of a patient with a large mediastinal tumor caused by neurofibromatosis type 1 in which airway obstruction was avoided through the use of a novel extra-long T-tube placement technique.
• 超音波気管支鏡を併用した血栓溶解療法に関する基礎研究

  稲毛 輝長, 藤野 孝介, 石綿 司, 本岡 大和, 氏家 秀樹, 新垣 雅人, 関 健史, 吉野 一郎, 安福 和弘

  気管支学 (NPO)日本呼吸器内視鏡学会 42 (Suppl.) S274 - S274 0287-2137 2020/06
• A novel approach for the complete extraction of large tumours in video-assisted thoracoscopic surgery.

  Masato Aragaki, Kichizo Kaga, Yasuhiro Hida, Tatsuya Kato, Yoshiro Matsui

  Journal of minimal access surgery 2020/01/28 [Refereed][Not invited]
   

  Background: Video-assisted thoracoscopic (VATS) lobectomy has recently become the standard for treating lung cancer. However, the complete removal of large tumours from the chest cavity is often difficult. Therefore, we developed a novel approach to extract large tumours from the wound without rib resection or fracture (the eXtraction of resected specimens through the Lower INterCostal route [XLINC] method). Subjects and Methods: In XLINC, a skin incision is made on the tenth intercostal space, and the resected lung tissue is extracted. This retrospective study included patients who underwent VATS lobectomy using XLINC in our institution from 2016 to 2018. As a control group, six patients who had undergone thoracotomy during VATS surgery due to a large tumour diameter were included in the conversion group. Results: Four men and six women (median age = 66 years, maximum median tumour diameter = 59 mm) were included in the study. The median length of the wound incision for XLINC was 4.5 (range: 4-8) cm. The median operative time was 183 min, and the estimated blood loss was 50 ml. Rib resection was not required, and no fractures were noted. The median length of hospital stay was 8 days. No patients developed major complications caused by XLINC. There were no significant differences, except in operation time and amount of blood loss, between the two groups. However, the XLINC group used fewer post-operative analgesics. Conclusion: Our report suggests that XLINC might be a simpler, less invasive procedure that could be used in patients with large tumours.
• 肺移植患者における超音波気管支鏡の安全性および有効性の検討

  氏家 秀樹, 加藤 達哉, 稲毛 輝長, 石綿 司, 新垣 雅人, 樋田 泰浩, 加賀 基知三, 若狭 哲

  移植 一般社団法人 日本移植学会 55 (Supplement) 383_2 - 383_2 0578-7947 2020 

  目的 気管支腔内超音波検査法（EBUS）は低侵襲かつ高い診断能を有する検査手技である。本研究では、肺移植待機患者および移植後患者の経過中に、悪性腫瘍が疑われた肺・リンパ節病変に対するEBUSの有用性を検討した。方法 2008年～2018年までの間にEBUSガイド下経気道的肺生検 (EBUS-GS-TBB, EBUS-TBNA)が施行された肺移植後患者及び待機患者に対し後方視的検討を行った。結果 全28例に対してEBUS-TBNA：20例、EBUS-GS-TBB：8例 が施行された。肺移植術後患者19例の内訳は、移植後に肺腫瘤を認め悪性腫瘍が疑われた11例、肺門及び縦隔リンパ節腫大を認め移植後リンパ増殖性疾患(PTLD)が疑われた8例であった。全症例において確定診断が可能であり、重篤な合併症を認めなかった。診断の内訳は、原発性肺癌6例、PTLD 4例、感染性疾患3例、良性疾患6例であった。PTLDが疑われた8例中、4例（50%）がPTLDと診断され、肺悪性腫瘍が疑われた11例中、6例(55%)で肺悪性腫瘍の確定診断が可能であった。また、肺移植待機9例のうち、5例（56%）にて肺悪性腫瘍の確定診断に至り、治療方針が変更された。結論 移植待機中の末期慢性肺疾患症例及び肺移植術前後症例におけるEBUSは、肺病変及び縦隔肺門リンパ節に対する安全かつ高精度な質的診断が可能な検査法と考えられた。
• Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: Study protocol for a phase III, multicenter randomized trial with two parallel groups of patients

  Haruko Yamamoto, Toshimitsu Hamasaki, Kaori Onda, Takashi Nojiri, Masato Aragaki, Nao Horie, Norihiro Sato, Yasuhiro Hida

  Trials 20 (1) 715 - 715 2019/12/11 [Refereed][Not invited]
   

  © 2019 The Author(s). Background: Recurrence of cancer after curative surgery is a major problem after most cancer treatments. Increased sympathetic activity during the perioperative period could promote cancer cell invasion to blood vessels and angiogenesis, resulting in cancer metastasis. Recent studies showed that use of beta blockers can be associated with the prolonged survival of patients with cancer. The objective of this study is to evaluate the preventive effects of landiolol hydrochloride, which is an ultra-short-acting beta-1-selective blocker that has been developed in Japan, on reducing recurrence of cancer after curative surgery for patients with lung cancer. Methods: The present study is a phase III, multicenter, randomized trial with two parallel groups of patients with lung cancer, comparing surgery alone and surgery with landiolol administration for three days during the perioperative period. A total of 400 patients will be enrolled from 12 Japanese institutions. The primary endpoint is two-year relapse-free survival and overall survival after curative surgery for lung cancer. The secondary endpoints are additional treatment after recurrence of cancer, safety events, and the incidence of postoperative complications. Discussion: The principal question addressed in this trial is whether landiolol can reduce recurrence of cancer after curative surgery for lung cancer. Trial registration: Japan Registry of Clinical Trials, jRCT2011180004. Registered 17 January 2019.
• Feasibility and safety of reduced-port video-assisted thoracoscopic surgery using a needle scope for pulmonary lobectomy- retrospective study.

  Aragaki M, Kaga K, Hida Y, Kato T, Matsui Y

  Annals of medicine and surgery 45 70 - 74 2019/09 [Refereed][Not invited]
  
• 肺移植未認定施設における肺移植トレーニングプログラムの有用性の検討 北海道での肺移植施設認定への取り組み

  加藤 達哉, 新垣 雅人, 長 靖, 道免 寛充, 樋田 泰浩, 七戸 俊明, 加賀 基知三, 平野 聡, 松居 喜郎

  北海道外科雑誌 北海道外科学会 64 (1) 43 - 50 0288-7509 2019/06 

  肺移植未認定施設において移植手術手技の修練は課題の一つである。大動物を使った修練は実践的であるものの、倫理的な問題や解剖がヒトと異なるという欠点は否めない。我々はシール法固定献体を用いたカダバートレーニングを併用することによる肺移植シミュレーションとしての有用性を検討した。いずれもドナーより両肺を摘出し、レシピエントに片肺移植を行った。各々の講習前後でトレーニング効果を受講者のアンケートにて分析した。ブタ生体では心拍下の肺動脈カニュレーションや血管吻合が可能となる。シール法固定献体では組織の状態は生体に近く、手技は実際の手術に近い感覚で行える。この2つを組み合わせることで、参加者の肺移植の各行程に対する理解と手術スキルが向上した。献体とブタ生体を組み合わせた肺移植手術トレーニングは肺移植未認定施設におけるトレーニングプログラムとして有用と考えられた。(著者抄録)
• 小児嚢胞性肺疾患に対する胸腔鏡下肺葉切除と手術時期の検討

  加賀 基知三, 本橋 雄介, 藤原 晶, 新垣 雅人, 加藤 達哉, 樋田 泰浩, 本多 昌平, 松居 喜郎

  小切開・鏡視外科学会雑誌 (NPO)小切開・鏡視外科学会 10 (1) 54 - 54 2185-2820 2019/06
• 不全分葉間に発生した肺癌に対する胸腔鏡下複合区域切除における赤外光胸腔鏡の有用性

  加藤 達哉, 新垣 雅人, 藤原 晶, 本橋 雄介, 樋田 泰浩, 福井 秀章, 松野 吉宏, 加賀 基知三, 松居 喜郎

  日本呼吸器外科学会雑誌 (NPO)日本呼吸器外科学会 33 (3) P57 - 2 0919-0945 2019/04 [Refereed][Not invited]
  
• 非移植認定施設における肺移植手術シミュレーションの有用性

  加藤 達哉, 新垣 雅人, 樋田 泰浩, 千葉 龍平, 本橋 雄介, 道免 寛充, 長 靖, 加賀 基知三, 松居 喜郎

  移植 (一社)日本移植学会 53 (総会臨時) 472 - 472 0578-7947 2018/09
• インドシアニングリーン蛍光胸腔鏡を用いた胸腔鏡下複数肺区域切除

  加藤 達哉, 新垣 雅人, 八木 優樹, 千葉 龍平, 樋田 泰浩, 加賀 基知三, 松井 喜郎

  小切開・鏡視外科学会雑誌 (NPO)小切開・鏡視外科学会 9 (1) 22 - 22 2185-2820 2018/06 [Refereed][Not invited]
  
• 食道癌手術既往のある肺切除症例の検討

  新垣 雅人, 加賀 基知三, 樋田 泰浩, 加藤 達哉, 久保田 玲子[中田], 八木 優樹, 千葉 龍平, 松居 喜郎

  北海道外科雑誌 北海道外科学会 62 (2) 182 - 182 0288-7509 2017/12
• 肺を温存して完全胸腔鏡下に摘除できた硝子血管型肺内キャッスルマン病の1例

  樋田 泰浩, 加賀 基知三, 新垣 雅人, 久保田 玲子, 臼井 葉月, 松居 喜郎, 井口 晶裕

  日本小児外科学会雑誌 (一社)日本小児外科学会 53 (5) 1087 - 1087 0288-609X 2017/08
• 術後肺瘻に対しEWS充填が有用であった1例

  臼井 葉月, 加賀 基知三, 樋田 泰浩, 新垣 雅人, 久保田 玲子[中田], 椎谷 洋彦, 松居 喜郎, 庄司 哲明, 品川 尚文

  北海道外科雑誌 北海道外科学会 62 (1) 85 - 85 0288-7509 2017/06
• cN1非小細胞肺癌の術前臨床因子と予後の解析

  新垣 雅人, 加賀 基知三, 植田 泰浩, 久保田 玲子, 椎谷 洋彦, 臼井 葉月, 松居 喜郎

  日本外科学会定期学術集会抄録集 (一社)日本外科学会 117回 SF - 4 2017/04
• Anomalous V2 of the left pulmonary vein detected using three-dimensional computed tomography in a patient with lung cancer: A case report

  Masato Aragaki, Yasuaki Iimura, Yusuke Yoshida, Naoto Hasegawa

  International Journal of Surgery Case Reports 37 208 - 210 2210-2612 2017 [Refereed][Not invited]
   

  We report one of the rare anatomical variations of the pulmonary vein wherein the left V2 drained into the inferior pulmonary vein. A 63-year-old man was referred to our hospital because of an abnormal shadow in the left lower lung field that was noted on chest X-ray. Computed tomography (CT) revealed a tumor in the left lower lobe. A biopsied tumor specimen was diagnosed as an adenocarcinoma, and thus, left lower lobectomy was performed. Preoperative three-dimensional CT revealed that an anomalous V2 of the left lung drained from the superior segment into the inferior pulmonary vein. This variation type was confirmed during thoracoscopic left lower lobectomy. We were able to perform left lower lobectomy with the preservation of the anomalous V2. The postoperative course was uneventful, and the patient was discharged on postoperative day 12. It is important to identify anatomical variations of the pulmonary vein and reliably preserve and process the affected area to prevent postoperative complications.
• 胸腺癌における腫瘍マーカーの有用性の検討

  椎谷 洋彦, 樋田 泰浩, 加賀 基知三, 新垣 雅人, 久保田 玲子[中田], 臼井 葉月, 松居 喜郎

  北海道外科雑誌 北海道外科学会 61 (2) 201 - 202 0288-7509 2016/12
• 非小細胞肺癌single staion cN2症例に対する手術先行治療の妥当性の検討

  樋田 泰浩, 加賀 基知三, 新垣 雅人, 久保田 玲子[中田], 椎谷 洋彦, 臼井 葉月, 松居 喜郎

  肺癌 (NPO)日本肺癌学会 56 (6) 693 - 693 0386-9628 2016/11
• [Transmanubrial Osteomuscular-sparing Approach for Resection of Superior Mediastinal Schwannoma].

  Aragaki M, Iimura Y, Sato N, Fukuda N, Miyazaki D, Umemoto K, Yoshida Y, Hasegawa N

  Kyobu geka. The Japanese journal of thoracic surgery 南江堂 69 (9) 760 - 763 0021-5252 2016/08 [Refereed][Not invited]
  
• [Mediastinal Mature Teratoma Necessitating Resection of Superior Vena Cava].

  Aragaki M, Iimura Y, Hasegawa N, Kaga K

  Kyobu geka. The Japanese journal of thoracic surgery 南江堂 68 (10) 845 - 849 0021-5252 2015/09 [Refereed][Not invited]
  
• Paraneoplastic Extralimbic Encephalitis Associated with Thymoma: A Case Report

  Masato Aragaki, Yasuaki Iimura, Kenichi Teramoto, Nagato Sato, Kazuyuki Hirose, Naoto Hasegawa

  ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY 21 (4) 399 - 402 1341-1098 2015 [Refereed][Not invited]
   

  Here we a report a rare case of extralimbic encephalitis associated with thymoma. A 66-year-old woman was admitted to our hospital with cramping in her right leg and inability to walk. Magnetic resonance imaging of the brain showed multifocal high intensity signals on T2 flare images in the cerebral cortex, and chest computed tomography showed a 5-cm anterior mediastinal mass, which was considered to be a thymoma. We speculated that she had paraneoplastic encephalitis associated with thymoma. She underwent a thymectomy and was diagnosed with type B1 thymoma. On postoperative day 6, her neurological symptoms began to improve. On postoperative day 31, she was discharged without complications. Limbic encephalitis is a paraneoplastic neurological syndromeassociated with thymoma, but extralimbic encephalitis has been described in the literature very rarely. We report the case of extralimbic encephalitis associated with thymoma along with a literature review.
• A Case of Castleman's Disease with Myasthenia Gravis

  Keidai Ishikawa, Tatsuya Kato, Masato Aragaki, Toshiro Ohbuchi, Sachiko Kimura, Yoshiro Matsui, Mitsuhito Kaji

  ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY 20 585 - 588 1341-1098 2014 [Refereed][Not invited]
   

  A rare case of Castleman's disease with myasthenia gravis is reported. A 55-year-old woman with bilateral ptosis, speech impairment, and severe dyspnea had been previously diagnosed with myasthenia gravis. Computed tomography showed a 5 cm x 3 cm paratracheal mass in the mediastinum, thought to be an ectopic thymoma. Two days after surgical resection, the patient suddenly developed dyspnea. Postoperative myasthenic crisis was diagnosed, and plasmapheresis was performed. Her general condition improved, and her subsequent course was uneventful. The final pathological diagnosis was mediastinal solitary Castleman's disease, hyaline vascular type. Castleman's disease with myasthenia gravis is especially rare. One of the serious complications is postoperative myasthenic crisis. For patients with myasthenia gravis, the rate of postoperative myasthenic crisis seems significantly higher in Castleman's disease patients than in patients with thymic epithelial tumors. Castleman's disease with myasthenia gravis is discussed along with a review of the literature.
• RASEF is a Novel Diagnostic Biomarker and a Therapeutic Target for Lung Cancer

  Hideto Oshita, Ryohei Nishino, Atsushi Takano, Takashi Fujitomo, Masato Aragaki, Tatsuya Kato, Hirohiko Akiyama, Eiju Tsuchiya, Nobuoki Kohno, Yusuke Nakamura, Yataro Daigo

  MOLECULAR CANCER RESEARCH 11 (8) 937 - 951 1541-7786 2013/08 [Refereed][Not invited]
   

  Genome-wide gene expression profiling revealed that the Ras and EF-hand domain containing (RASEF) transcript was significantly transactivated in the majority of lung cancers. Using lung cancer cells, transient expression of RASEF promoted cell growth, whereas RASEF knockdown not only reduced its expression but resulted in growth suppression of the cancer cells. Immunohistochemical staining using tumor tissue microarrays consisting of 341 archived non-small cell lung cancers (NSCLC) revealed the association of strong RASEF positivity with poor prognosis (P = 0.0034 by multivariate analysis). Mechanistically, RASEF interacted with extracellular signal-regulated kinase (ERK) 1/2 and enhanced ERK1/2 signaling. Importantly, inhibiting the interaction between RASEF and ERK1/2 using a cell-permeable peptide that corresponded to the ERK1/2-interacting site of RASEF, suppressed growth of lung cancer cells. This study demonstrates that elevated RASEF promoted cell growth via enhanced ERK signaling and is associated with poor prognosis of NSCLC. Implications: RASEF may play an important role in lung carcinogenesis and could serve as a vaiable prognostic biomarker and target for the development of new molecular therapies. (C) 2013 AACR.
• Optimal predictive value of preoperative serum carcinoembryonic antigen for surgical outcomes in stage I non-small cell lung cancer: differences according to histology and smoking status.

  Tatsuya Kato, Keidai Ishikawa, Masato Aragaki, Masaaki Sato, Kenzo Okamoto, Tetsuya Ishibashi, Koji Oba, Mitsuhito Kaji

  Journal of surgical oncology 107 (6) 619 - 24 0022-4790 2013/05 [Refereed][Not invited]
   

  BACKGROUND: The cutoff value of preoperative serum carcinoembryonic antigen (CEA) levels has not been investigated using appropriate subgroup analyses for non-small cell lung carcinoma (NSCLC). This study was undertaken to determine whether the most predictive preoperative CEA level for risk of recurrence differs according to histological type, and how smoking status influences predictive values in Stage I NSCLC. METHODS: Subjects comprised Stage I NSCLC patients [141 patients with adenocarcinoma (ADC) and 36 with squamous cell carcinoma (SCC)]. RESULTS: In patients with Stage I ADC, recurrence-free survival (RFS) differed most significantly at a preoperative CEA level of 2.5 ng/ml, regardless of smoking status. Cases with preoperative CEA >2.5 ng/ml correlated with male sex, high maximum standard uptake value on (18) F-fluorodeoxyglucose positron emission tomography, poorer histopathological grade, lymphatic invasion, and smoking status. Importantly, preoperative CEA >2.5 ng/ml was identified as an independent risk factor for recurrence (P = 0.0015). Conversely, in patients with SCC, a preoperative CEA level of 3.0 ng/ml was the most predictive threshold. CONCLUSIONS: Thresholds of preoperative CEA should be considered when predicting risk of relapse, even if these levels are within normal limits, as optimal cutoff levels may vary according to histological type.
• Endobronchial closure of a bronchopleural fistula using a fibrin glue-coated collagen patch and fibrin glue

  Keidai Ishikawa, Tatsuya Kato, Masato Aragaki, Ryunosuke Hase, Toyohiro Saikai, Yoshiro Matsui, Mitsuhito Kaji

  Annals of Thoracic and Cardiovascular Surgery 19 (6) 423 - 427 1341-1098 2013 [Refereed][Not invited]
   

  Bronchopleural fistulas associated with empyema can occur as life-threatening sequelae after pulmonary resection, occurring most frequently after pneumonectomy. Three bronchopleural fistulas, 5-6 mm in diameter, were successfully treated using a fibrin gluecoated collagen patch (FGCCP) and fibrin glue (FG) at the site of a bronchopleural fistula. Through the clinical experiences, we introduce the methodology to perform the endobronchial closure of bronchopleural fistulas. Data were collected by reviewing the clinical charts of patients diagnosed with post-lobectomy bronchopleural fistula at Sapporo Minami-Sanjo Hospital from June 2004 to December 2010. Bronchopleural fistula was diagnosed by means of endoscopic visualization. Three cases of post-lobectomy and one case of post-pneumonectomy bronchopleural fistula were collected. A FGCCP fragment was packed within the fistula, and the fragment grasped with the forceps was kept in this position for approximately a minute, a time during which a FGCCP becomes adhesive, and the patch fragment was released. After releasing the patch fragment, the FG was applied directly on the FGCCP using a two-channel catheter. There have been few reports of the bronchoscopic closure of bronchopleural fistulas using a FGCCP and FG. Closure of small bronchopleural fistulas with the application of a FGCCP and FG may offer a valuable therapeutic alternative. © 2013 The Editorial Committee of Annals of Thoracic and Cardiovascular Surgery. All rights reserved.
• Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients

  Tatsuya Kato, Yataro Daigo, Masato Aragaki, Keidai Ishikawa, Masaaki Sato, Mitsuhito Kaji

  JOURNAL OF SURGICAL ONCOLOGY 106 (4) 423 - 430 0022-4790 2012/09 [Refereed][Not invited]
   

  Background This study examined the expression of CDC20 in human non-small cell lung cancer (NSCLC), explored its clinicopathological significance, and evaluated as a potential prognostic marker. Methods A total of 362 cases of NSCLCs were analyzed immunohistochemically on tissue microarrays (TMAs). Additionally, the immunoreactivity of mitotic arrest defective protein 2 (MAD2) was also studied. The clinicopathological implications of these molecules were analyzed statistically. Results High-level CDC20 protein expression (CDC20-H) was detected in 71 cases (19.6%). Additionally, CDC20-H was correlated with male sex, pT status, pleural invasion, and non-adenocarcinoma (non-ADC) histology. Significant correlation between CDC20 and MAD2 expression was found. NSCLC patients with tumor exhibiting CDC20-H showed significantly shorter 5-year overall survival (P?=?0.0007). According to subset analyses, CDC20-H was associated with shorter survival than CDC20-L only among ADC patients (P?=?0.0008), and not among squamous cell carcinoma (SCC) patients (P?=?0.5100). Importantly, CDC20-H was also identified as an independent prognostic factor in multivariate analysis (P?=?0.0065). Conclusions CDC20 was a negative prognostic marker with significance in patients with resected NSCLC, particularly those with ADC histology. These results provide additional information for determining postoperative adjuvant treatment. J. Surg. Oncol. 2012; 106:423430. (c) 2012 Wiley Periodicals, Inc.
• Angiolymphatic invasion exerts a strong impact on surgical outcomes for stage I lung adenocarcinoma, but not non-adenocarcinoma

  Tatsuya Kato, Keidai Ishikawa, Masato Aragaki, Masaaki Sato, Kenzo Okamoto, Tetsuya Ishibashi, Mitsuhito Kaji

  LUNG CANCER 77 (2) 394 - 400 0169-5002 2012/08 [Refereed][Not invited]
   

  Angiolymphatic invasion (ALL), representing lymphatic invasion (Ly) and intratumoral vascular invasion (V), is considered to be a useful prognostic factor for pathological stage I non-small cell lung carcinoma (NSCLC). However, the types of tumor for which prognoses are most influenced by ALL positivity have not previously been discussed, nor has the question of whether these findings should influence postoperative therapeutic decision-making after complete resection. The present study investigated 195 cases of stage I NSCLC treated by potentially curative surgical resection of the primary tumor and systematic lymphadenectomy. ALI-positive (ALI(+)) results were found in 31.8% of tumors, and 5.1% exhibited both Ly(+) and V(+). Five-year recurrence-free survival was significantly lower in ALI(+) cases (50.6%) than in AL(-) cases (85.9%; p < 0.0001, log-rank test). In particular, 5-year recurrence-free survival rate was only 10.0% for Ly(+)V(+) cases. ALI(+) correlated with high age, male sex, tumor size (>2.0 cm), elevated preoperative serum carcinoembryonic antigen level (>= 5.0 ng/mL), high maximum standard uptake value (SUVmax) on F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) (>= 5.0), pleural invasion, and histological classification of non-adenocarcinoma (ADC). According to histopathological subset analyses. ALIN was associated with shorter recurrence-free survival than ALI() only among ADC patients (p<0.0001, log-rank test), and not among non-ADC patients (p = 0.7710). High preoperative serum CEA level, high SUVmax on FDG-PET, pleural invasion, Ly(+), and V(+) were significant risk factors for recurrence in univariate Cox survival analysis among stage I ADC patients. Importantly, Ly(+) and V(+) were identified as independent risk factors for recurrence by multivariate analysis. Histopathological detection of ALI as a risk factor for recurrence should be considered for inclusion in the staging criteria and as additional information for determining postoperative adjuvant treatment of stage I NSCLC, particularly among ADC patients, but not among non-ADC patients. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
• Overexpression of KIAA0101 predicts poor prognosis in primary lung cancer patients

  Tatsuya Kato, Yataro Daigo, Masato Aragaki, Keidai Ishikawa, Masaaki Sato, Mitsuhito Kaji

  LUNG CANCER 75 (1) 110 - 118 0169-5002 2012/01 [Refereed][Not invited]
   

  High expression of KIAA0101 (p15(PAF)/OEATC-1) which contains a proliferating cell nuclear antigen (PCNA)-binding motif, a key factor in DNA repair and/or apoptosis and cell cycle regulation, has been observed in a variety of human malignancies. The aim of this study was to observe the expression of KIAA0101 in human non-small-cell lung cancer (NSCLC), explore its clinicopathological significance and evaluate KIAA0101 expression as a potential prognostic marker. KIAA0101 transcript was found to be overexpressed in the great majority of lung cancers by semi-quantitative RT-PCR. A total of 357 NSCLCs were analyzed immunohistochemically on tissue microarrays. High-level KIAA0101 expression was observed in 33.9% (121 of 357 cases), and correlated with male gender (P < 0.0001), tumor progression (pT status) (P=0.0008), lymph node metastasis (pN status) (P=0.0003), non-adenocarcinoma histological classification (P < 0.0001), and smoking history (P < 0.0001), but not with patient age or pleural invasion. Patients with tumors displaying high-level KIAA0101 expression showed significantly shorter survival (P < 0.0001, log-rank test). Similarly, gender, pT status, pN status, pleural invasion, histological classification, and smoking history were significant prognostic markers in univariate Cox survival analysis. Importantly, high-level KIAA0101 expression was also identified as an independent prognostic factor by multivariate analysis (P=0.0320). These results provide additional information for determining postoperative adjuvant treatment of NSCLC. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
• Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients

  Tatsuya Kato, Yataro Daigo, Masato Aragaki, Keidai Ishikawa, Masaaki Sato, Satoshi Kondo, Mitsuhito Kaji

  LUNG CANCER 74 (1) 124 - 131 0169-5002 2011/10 [Refereed][Not invited]
   

  High-level expression of mitotic arrest defective protein 2 (MAD2), a central component of the spindle assembly checkpoint, has been observed in a variety of human malignancies. Aim of the present study was to observe the expression of MAD2 in human non-small-cell lung cancer (NSCLC) and explore its clinicopathologic significance and evaluate MAD2 expression as a prognostic marker. MAD2 transcript was found to be overexpressed in the great majority of lung cancers by semi-quantitative RT-PCR. A total of 358 NSCLCs were analyzed immunohistochemically on tissue microarrays. High-level MAD2 expression was observed in 26.3% (94 of 358 cases), and correlated with male sex (P = 0.0002), tumor progression (pT status) (P = 0.0009), visceral or parietal pleural invasion (P = 0.0151), non-adenocarcinoma, histological classification (P < 0.0001), and smoking history (P = 0.0022), but not with patient age or lymph node metastasis (pN status). Patients with tumors displaying high-level MAD2 expression showed significantly shorter survival (P < 0.0001, log-rank test). Similarly, gender, pT status, pN status, pleural invasion, histological classification, and smoking history were significant prognostic markers in univariate Cox survival analysis. Importantly, high-level MAD2 expression was also identified as an independent prognostic factor by multivariate analysis (P = 0.0076). These results provide additional prognostic information for surgical treatment of NSCLC. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
• 肺癌の新規予後因子、治療標的分子としてのLCAS1-LASK1の機能解析(LCAS1-LASK1 ldnase pathway as a novel prognostic biomarker and therapeutic target for lung cancer)

  新垣 雅人, 醍醐 弥太郎, 角田 卓也, 近藤 哲, 中村 祐輔

  日本癌学会総会記事 70回 112 - 112 0546-0476 2011/09
• Characterization of a Cleavage Stimulation Factor, 3 ' pre-RNA, Subunit 2, 64 kDa (CSTF2) as a Therapeutic Target for Lung Cancer

  Masato Aragaki, Koji Takahashi, Hirohiko Akiyama, Eiju Tsuchiya, Satoshi Kondo, Yusuke Nakamura, Yataro Daigo

  CLINICAL CANCER RESEARCH 17 (18) 5889 - 5900 1078-0432 2011/09 [Refereed][Not invited]
   

  Purpose: This study aims to discover novel biomarkers and therapeutic targets for lung cancers. Experimental Design: We screened for genes showing elevated expression in the majority of lung cancers by genome-wide gene expression profile analysis of 120 lung cancers obtained by cDNA microarray representing 27,648 genes or expressed sequence tags. In this process, we detected a gene encoding cleavage stimulation factor, 3' pre-RNA, subunit 2, 64 kDa (CSTF2) as a candidate. Immunohistochemical staining using tissue microarray consisting of 327 lung cancers was applied to examine the expression of CSTF2 protein and its prognostic value. A role of CSTF2 in cancer cell growth was examined by siRNA experiments. Results: Northern blot and immunohistochemical analyses detected the expression of CSTF2 only in testis among 16 normal tissues. Immunohistochemical analysis using tissue microarray showed an association of strong CSTF2 expression with poor prognosis of patients with non-small cell lung cancer (P = 0.0079), and multivariate analysis showed that CSTF2 positivity is an independent prognostic factor. In addition, suppression of CSTF2 expression by siRNAs suppressed lung cancer cell growth, whereas exogenous expression of CSTF2 promoted growth and invasion of mammalian cells. Conclusions: CSTF2 is likely to play an important role in lung carcinogenesis and be a prognostic biomarker in the clinic. Clin Cancer Res; 17(18); 5889-900. (C) 2011 AACR.
• がん抑制遺伝子 肺癌に関わる新規癌抗原LCAT1の同定と機能解析(Tumor-suppressor genes Identification of a novel oncoprotein LCAT1 involeved in lung carcinogenesis)

  藤友 崇, 醍醐 弥太郎, 新垣 雅人, 松田 浩一, 角田 卓也, 中村 祐輔

  日本癌学会総会記事 69回 65 - 65 0546-0476 2010/08
• Wnt Inhibitor Dickkopf-1 as a Target for Passive Cancer Immunotherapy

  Nagato Sato, Takumi Yamabuki, Atsushi Takano, Junkichi Koinuma, Masato Aragaki, Ken Masuda, Nobuhisa Ishikawa, Nobuoki Kohno, Hiroyuki Ito, Masaki Miyamoto, Haruhiko Nakayama, Yohei Miyagi, Eiju Tsuchiya, Satoshi Kondo, Yusuke Nakamura, Yataro Daigo

  CANCER RESEARCH 70 (13) 5326 - 5336 0008-5472 2010/07 [Refereed][Not invited]
   

  Dickkopf-1 (DKK1) is an inhibitor of Wnt/beta-catenin signaling that is overexpressed in most lung and esophageal cancers. Here, we show its utility as a serum biomarker for a wide range of human cancers, and we offer evidence favoring the potential application of anti-DKK1 antibodies for cancer treatment. Using an original ELISA system, high levels of DKK1 protein were found in serologic samples from 906 patients with cancers of the pancreas, stomach, liver, bile duct, breast, and cervix, which also showed elevated expression levels of DKK1. Additionally, anti-DKK1 antibody inhibited the invasive activity and the growth of cancer cells in vitro and suppressed the growth of engrafted tumors in vivo. Tumor tissues treated with anti-DKK1 displayed significant fibrotic changes and a decrease in viable cancer cells without apparent toxicity in mice. Our findings suggest DKK1 as a serum biomarker for screening against a variety of cancers, and anti-DKK1 antibodies as potential theranostic tools for diagnosis and treatment of cancer. Cancer Res; 70(13); 5326-36. (C) 2010 AACR.
• 呼吸器外科手術における三次元再構築CT画像の有用性について

  加賀 基知三, 新垣 雅人, 川田 将也, 新関 浩人, 樋田 泰浩, 平野 聡, 近藤 哲

  日本外科学会雑誌 (一社)日本外科学会 109 (臨増2) 481 - 481 0301-4894 2008/04
• 病理学的診断に基づくGGOを伴った末梢小型肺癌に対する二期的手術の検討

  川田 将也, 加賀 基知三, 樋田 泰浩, 新関 浩人, 新垣 雅人, 平野 聡, 近藤 哲

  日本外科学会雑誌 (一社)日本外科学会 109 (臨増2) 670 - 670 0301-4894 2008/04
• 特発性間質性肺炎を伴う原発性肺癌切除例の長期予後

  新関 浩人, 樋田 泰浩, 新垣 雅人, 川田 将也, 加賀 基知三, 平野 聡, 近藤 哲

  肺癌 (NPO)日本肺癌学会 47 (7) 956 - 956 0386-9628 2007/12

MISC

• Pulmonary Vein-First Lobectomy May Improve Postoperative Prognosis in Patients with Clinically N0 Primary Lung Cancer: A Multicenter Propensity Score-Matched Study

  SHIIYA Haruhiko, UJIIE Hideki, OTSUKA Shohei, YAMASAKI Hiroshi, SASAKI Akihiro, CHIBA Ryohei, NOMURA Shunsuke, OHTAKA Kazuto, FUJIWARA-KURODA Aki, ARAGAKI Masato, KATO Tatsuya  薬理と臨床  34-  (2)  2024
• Modified Anterior Approach with Horizontal Open-Thoracotomy-View in Robot-Assisted Thoracic Surgery

  OHTAKA Kazuto, OTSUKA Shohei, YAMASAKI Hiroshi, SASAKI Akihiro, SHIIYA Haruhiko, FUJIWARA-KURODA Akli, UJIIE Hideki, ARAGAKI Masato, KATO Tatsuya  薬理と臨床  34-  (2)  2024
• Reduced port Robot-assisted thoracic surgery(RATS)の未来

  氏家秀樹, 大塚将平, 佐々木明洋, 山崎洋, 椎谷洋彦, 大高和人, 藤原晶, 新垣雅人, 江花弘基, 加藤達哉  気管支学  46-  2024
• 薬物療法後の縦隔内再発に対してロボット支援下腫瘍摘除術を施行した二相型胸膜中皮腫の1例

  岡村峻, 佐々木明洋, 大塚将平, 山崎洋, 椎谷洋彦, 大高和人, 藤原晶, 氏家秀樹, 新垣雅人, 加藤達哉  日本呼吸器外科学会総会(Web)  41st-  2024
• TOUCHCLASSを用いた手術教育システムの構築

  新垣雅人, 大塚将平, 佐々木明洋, 山崎洋, 椎谷洋彦, 大高和人, 藤原晶, 氏家秀樹, 加藤達哉  日本呼吸器外科学会総会(Web)  41st-  2024
• Reduced port Robot-assisted thoracic surgery(RATS)の定型化の取り組み-利点および欠点の検討

  氏家秀樹, 大塚将平, 佐々木明洋, 山崎洋, 椎谷洋彦, 大高和人, 藤原晶, 新垣雅人, 江花弘基, 加藤達哉  日本呼吸器外科学会総会(Web)  41st-  2024
• 北海道大学病院呼吸器外科における医師のオンコール体制の導入

  藤原晶, 大塚将平, 佐々木明洋, 山崎洋, 椎谷洋彦, 大高和人, 氏家秀樹, 新垣雅人, 加藤達哉  日本呼吸器外科学会総会(Web)  41st-  2024
• 左上葉肺癌に対する肺葉切除と区域切除の傾向スコアマッチングを用いた長期成績比較

  竹野巨樹, 野村俊介, 大塚将平, 山崎洋, 佐々木明洋, 椎谷洋彦, 大高和人, 藤原晶, 氏家秀樹, 新垣雅人, 千葉龍平, 椎名伸行, 加地苗人, 加藤達哉  日本呼吸器外科学会総会(Web)  41st-  2024
• 胸膜中皮腫術後のアスペルギルス膿胸に対し外用抗真菌薬の胸腔内塗布が有効であった1例

  野村俊介, 藤原晶, 大塚将平, 竹野巨樹, 山崎洋, 佐々木明洋, 椎谷洋彦, 大高和人, 氏家秀樹, 新垣雅人, 長靖, 加藤達哉  日本呼吸器外科学会総会(Web)  41st-  2024
• 7気管輪の気管環状切除を施行した下部気管腺様嚢胞癌の1例

  佐々木明洋, 大塚将平, 山崎洋, 椎谷洋彦, 大高和人, 藤原晶, 氏家秀樹, 新垣雅人, 加藤達哉  日本呼吸器外科学会総会(Web)  41st-  2024
• 当院におけるReduced port Robot-assisted thoracic surgery(RATS)の定型化の取り組み

  氏家秀樹, 竹野巨樹, 佐々木明洋, 山崎洋, 野村俊介, 椎谷洋彦, 大高和人, 藤原晶, 新垣雅人, 加藤達哉  日本外科学会定期学術集会(Web)  124th-  2024
• 肺静脈先行処理は原発性肺癌術後の再発を抑制する可能性がある-多施設共同研究-

  椎谷洋彦, 氏家秀樹, 新垣雅人, 藤原晶, 大高和人, 野村俊介, 千葉龍平, 加藤達哉  日本外科学会定期学術集会(Web)  124th-  2024
• 前方アプローチ(対面倒立視野)によるロボット支援下肺葉切除術

  大高和人, 竹野巨樹, 佐々木明洋, 山崎洋, 野村俊介, 藤原晶, 氏家秀樹, 新垣雅人, 加藤達哉  日本ロボット外科学会学術集会プログラム・抄録集  16th-  2024
• 肺類上皮血管内皮腫と肺腺癌が混在した多発肺結節影の1例

  藤原晶, 山崎雅久, 千葉龍平, 野村俊介, 武藤潤, 氏家秀樹, 新垣雅人, 加賀基知三, 若林健人, 松野吉宏, 加藤達哉  日本臨床外科学会雑誌  85-  (2)  2024
• 当院におけるReduced port RATSの取り組み

  氏家秀樹, 竹野巨樹, 佐々木明洋, 山崎洋, 野村俊介, 大高和人, 藤原晶, 新垣雅人, 加藤達哉  日本肺癌学会学術集会号  64th (CD-ROM)-  2023
• 小児に対する胸腔鏡下肺切除術の成績と課題

  加賀基知三, 河原仁守, 藤原晶, 新垣雅人, 氏家秀樹, 本多昌平, 武冨紹信, 加藤達哉  日本内視鏡外科学会総会(Web)  36th-  2023
• 胸腺癌27例の手術治療成績~2施設共同研究~

  新垣雅人, 千葉龍平, 藤原晶, 氏家秀樹, 大高和人, 野村俊介, 佐々木明洋, 山崎洋, 竹野巨樹, 加地苗人, 加藤達哉  日本胸部外科学会定期学術集会(Web)  76th-  2023
• Reduced port RATSの取り組み-Uniportal RATS確立へ向けて

  氏家秀樹, 竹野巨樹, 佐々木明洋, 山崎洋, 野村俊介, 大高和人, 藤原晶, 新垣雅人, 加藤達哉  日本胸部外科学会定期学術集会(Web)  76th-  2023
• 左上葉切除後の脳梗塞発症予防として肺静脈心嚢内処理を施行した症例の検討

  武藤潤, 山崎雅久, 千葉龍平, 野村俊介, 藤原晶, 氏家秀樹, 新垣雅人, 加賀基知三, 加藤達哉  日本呼吸器外科学会総会(Web)  40th-  2023
• ドナー肺を体外肺灌流と10°C保存した後に両側肺葉移植を施行した一例

  新垣雅人, 新垣雅人, 稲毛輝長, 川島光明, 谷口大輔, 石綿司, 氏家秀樹, 藤原晶, 大高和人, 椎谷洋彦, 加藤達哉, 安福和弘, KESHAVJEE Shaf, CYPEL Mercelo  日本移植学会総会プログラム抄録集  59th (Web)-  2023
• PRECLINICAL EVALUATION OF THIN CONVEX PROBE ENDOBRONCHIAL ULTRASOUND-GUIDED TRANSBRONCHIAL NEEDLE ASPIRATION FOR INTRAPULMONARY LESIONS

  Tsukasa Ishiwata, Terunaga Inage, Alexander Gregor, Yamato Motooka, Harley Chan, Masato Aragaki, Nicholas Bernards, Zhenchian Chen, Hideki Ujiie, Tomonari Kinoshita, Andrew Effat, Koichiro Tatsumi, Kazuhiro Yasufuku  CHEST  160-  (4)  2031A  -2032A  2021/10
• 肺移植患者におけるEBUS(超音波気管支鏡)の役割

  氏家秀樹, 氏家秀樹, 加藤達哉, 稲毛輝長, 石綿司, 新垣雅人, 新垣雅人, 樋田泰浩, 加賀基知三, KESHAVJEE Shaf, YASUFUKU Kazuhiro  日本肺および心肺移植研究会プログラム・抄録集  36th-  2020
• 小児嚢胞性肺疾患に対する胸腔鏡下肺葉切除と手術時期の検討

  加賀 基知三, 本橋 雄介, 藤原 晶, 新垣 雅人, 加藤 達哉, 樋田 泰浩, 本多 昌平, 松居 喜郎  小切開・鏡視外科学会雑誌  10-  (1)  54  -54  2019/06  [Not refereed][Not invited]
  
• 左冠動脈閉鎖・僧帽弁閉鎖不全を合併した肺葉内肺分画症の1例

  本橋 雄介, 藤原 晶, 新垣 雅人, 加藤 達哉, 樋田 泰浩, 加賀 基知三, 新井 洋輔, 加藤 伸康, 橘 剛, 松居 喜郎  日本臨床外科学会雑誌  80-  (5)  1029  -1029  2019/05  [Not refereed][Not invited]
  
• 血小板増多を示し、腫瘍内に髄外造血巣を伴ったAB型胸腺腫の一例

  若林 健人, 福井 秀章, 高桑 恵美, 岡田 宏美, 新垣 雅人, 外丸 詩野, 三橋 智子, 松野 吉宏  日本病理学会会誌  108-  (1)  475  -475  2019/04
• MALTリンパ腫合併胸腺癌の一例

  福井 秀章, 若林 健人, 高桑 恵美, 岡田 宏美, 合田 智宏, 新垣 雅人, 三橋 智子, 松野 吉宏  日本病理学会会誌  108-  (1)  475  -476  2019/04
• 小児外科領域における真の低侵襲手術とは? 小児嚢胞性肺疾患に対する胸腔鏡下肺葉切除と手術時期の検討

  加賀 基知三, 本橋 雄介, 藤原 晶, 新垣 雅人, 加藤 達哉, 樋田 泰浩, 本多 昌平, 松居 喜郎  日本外科学会定期学術集会抄録集  119回-  WS  -4  2019/04  [Not refereed][Not invited]
  
• ハイブリッド手術室における胸腔鏡下触知困難肺腫瘍部分切除のナビゲーションと切除肺のマージン確認(OS MaRCH法)

  樋田 泰浩, 加賀 基知三, 加藤 達哉, 新垣 雅人, 藤原 晶, 本橋 雄介, 松居 喜郎  日本外科学会定期学術集会抄録集  119回-  SF  -5  2019/04  [Not refereed][Not invited]
  
• 肺癌に対する薬物療法の進歩と外科治療の役割 免疫チェックポイント阻害剤時代の根治的化学放射線療法後の肺切除の役割

  樋田 泰浩, 加賀 基知三, 加藤 達哉, 新垣 雅人, 藤原 晶, 本橋 雄介, 松居 喜郎  日本呼吸器外科学会雑誌  33-  (3)  S  -2  2019/04  [Not refereed][Not invited]
  
• 異常血管の灌流領域の確認と区域間同定に赤外光胸腔鏡を用いた肺葉内肺分画症の一例

  本橋 雄介, 加藤 達哉, 新垣 雅人, 藤原 晶, 樋田 泰浩, 加賀 基知三, 松居 喜郎  日本呼吸器外科学会雑誌  33-  (3)  V8  -1  2019/04  [Not refereed][Not invited]
  
• ハイブリッド手術室における肺腫瘍のナビゲーションと切除肺のマージン確認(OS MaRCH法)

  樋田 泰浩, 加賀 基知三, 加藤 達哉, 新垣 雅人, 藤原 晶, 本橋 雄介, 松居 喜郎  日本呼吸器外科学会雑誌  33-  (3)  O10  -4  2019/04  [Not refereed][Not invited]
  
• 小児胸腔鏡手術-小児外科医と呼吸器外科医の立場から- 小児呼吸器疾患に対する胸腔鏡手術の現状と課題

  新垣 雅人, 加賀 基知三, 樋田 泰浩, 加藤 達哉, 藤原 晶, 本橋 雄介, 本多 昌平, 松居 喜郎  日本内視鏡外科学会雑誌  23-  (7)  PD15  -4  2018/12  [Not refereed][Not invited]
  
• Reduced Port VATSの短期および長期成績 二窓法および細径光学視管を用いた一窓法によるReduced port surgeryの実際と成績

  加賀 基知三, 樋田 泰浩, 加藤 達哉, 新垣 雅人, 藤原 晶, 本橋 雄介, 松居 喜郎  日本内視鏡外科学会雑誌  23-  (7)  WS19  -3  2018/12  [Not refereed][Not invited]
  
• 大学病院における胸腔鏡手術の教育体制

  樋田 泰浩, 加賀 基知三, 加藤 達哉, 新垣 雅人, 藤原 晶  日本内視鏡外科学会雑誌  23-  (7)  OS104  -1  2018/12  [Not refereed][Not invited]
  
• 小児・新生児に対するReduced Port VATSによる肺葉切除

  加賀 基知三, 千葉 龍平, 八木 優樹, 久保田 玲子, 新垣 雅人, 加藤 達哉, 樋田 泰浩, 松居 喜郎  日本呼吸器外科学会雑誌  32-  (3)  O13  -1  2018/04  [Not refereed][Not invited]
  
• 触知困難肺腫瘍のone-stop solution、術中病変マーキングと切除肺のマージン確認(OS MaRCH法)

  樋田 泰浩, 加賀 基知三, 加藤 達哉, 新垣 雅人, 八木 優樹, 千葉 龍平, 松居 喜郎  日本呼吸器外科学会雑誌  32-  (3)  O26  -2  2018/04  [Not refereed][Not invited]
  
• 巨大縦隔神経線維腫症に対して可及的切除とTチューブ挿入により気道狭窄を回避できた1例

  加藤 達哉, 新垣 雅人, 八木 優樹, 千葉 龍平, 樋田 泰浩, 加賀 基知三, 松居 喜郎  日本呼吸器外科学会雑誌  32-  (3)  O32  -1  2018/04  [Not refereed][Not invited]
  
• 食道癌手術既往のある肺癌手術症例の検討

  新垣 雅人, 加賀 基知三, 樋田 泰浩, 加藤 達哉, 八木 優樹, 千葉 龍平, 松居 喜郎  日本呼吸器外科学会雑誌  32-  (3)  P10  -6  2018/04  [Not refereed][Not invited]
  
• 胸腔鏡下手術における下位肋間経路による新しい切除臓器の創外摘出法(eXtraction method of resected specimen through the Lower INterCostal route-XLINC-)

  新垣 雅人, 加賀 基知三, 樋田 泰浩, 加藤 達哉, 八木 優樹, 千葉 龍平, 松居 喜郎  日本外科学会定期学術集会抄録集  118回-  1796  -1796  2018/04  [Not refereed][Not invited]
  
• 胸腔鏡手術における切除肺の創外摘出法の工夫

  千葉 龍平, 加賀 基知三, 樋田 泰浩, 加藤 達哉, 新垣 雅人, 久保田 玲子, 八木 優樹, 松居 喜郎  日本臨床外科学会雑誌  79-  (3)  619  -620  2018/03  [Not refereed][Not invited]
  
• 根治的化学放射線療法後再発・再燃肺癌に対するサルベージ手術と周術期合併症の予防

  樋田 泰浩, 加賀 基知三, 加藤 達哉, 新垣 雅人, 久保田 玲子[中田], 八木 優樹, 千葉 龍平, 松居 喜郎  肺癌  57-  (7)  917  -918  2017/12  [Not refereed][Not invited]
  
• 外科的切除を行った縦隔脂肪肉腫の3症例

  千葉 龍平, 加賀 基知三, 樋田 泰浩, 八木 優樹, 久保田 玲子, 新垣 雅人, 加藤 達哉, 松居 喜郎  肺癌  57-  (7)  919  -919  2017/12  [Not refereed][Not invited]
  
• Reduced port surgery・Single port VATS lobectomy:標準化できるのか?標準化するのか? 二窓法および細径光学視管を用いた一窓法によるReduced port surgery肺葉切除の適応

  加賀 基知三, 樋田 泰浩, 加藤 達哉, 新垣 雅人, 千葉 龍平, 八木 優樹, 久保田 玲子, 松居 喜郎  日本内視鏡外科学会雑誌  22-  (7)  WS2  -2  2017/12  [Not refereed][Not invited]
  
• 切除肺創外摘出法の工夫

  新垣 雅人, 加賀 基知三, 樋田 泰浩, 加藤 達哉, 八木 優樹  日本内視鏡外科学会雑誌  22-  (7)  SF012  -03  2017/12  [Not refereed][Not invited]
  
• 先天性嚢胞性肺疾患に対する胸腔鏡下肺葉切除の適応と限界

  加賀 基知三, 千葉 龍平, 八木 優樹, 久保田 玲子, 新垣 雅人, 加藤 達哉, 樋田 泰浩, 松居 喜郎  日本気胸・嚢胞性肺疾患学会雑誌  17-  (2)  96  -96  2017/08  [Not refereed][Not invited]
  
• 肋骨弓下切開による摘出肺創外摘出法の工夫

  新垣 雅人, 加賀 基知三, 樋田 泰浩, 加藤 達哉, 久保田 玲子, 八木 優樹, 千葉 龍平, 松居 喜郎  小切開・鏡視外科学会雑誌  8-  (1)  43  -43  2017/05  [Not refereed][Not invited]
  
• 肺癌に対するTKI・SBRT時代のサルベージ手術 局所進行非小細胞肺癌に対する根治的化学放射線療法後肺切除の認容性の検討

  樋田 泰浩, 加賀 基知三, 新垣 雅人, 久保田 玲子[中田], 椎谷 洋彦, 臼井 葉月, 松居 喜郎  日本外科学会定期学術集会抄録集  117回-  PD  -6  2017/04  [Not refereed][Not invited]
  
• 小型肺癌の治療戦略 原発腫瘍のmaxSUVを指標とした非浸潤癌に対する積極的縮小手術の妥当性

  樋田 泰浩, 加賀 基知三, 新垣 雅人, 中田 玲子, 椎谷 洋彦, 臼井 葉月, 松居 喜郎  日本呼吸器外科学会雑誌  31-  (3)  SY  -6  2017/04  [Not refereed][Not invited]
  
• One window & puncture法を用いた肺葉切除・区域切除術の検討

  新垣 雅人, 加賀 基知三, 樋田 泰浩, 久保田 玲子, 椎谷 洋彦, 臼井 葉月, 松居 喜郎  日本呼吸器外科学会雑誌  31-  (3)  O20  -3  2017/04  [Not refereed][Not invited]
  
• 局所進行肺癌に対する根治的化学放射線療法後の肺切除術の認容性

  樋田 泰浩, 加賀 基知三, 新垣 雅人, 久保田 玲子[中田], 椎谷 洋彦, 臼井 葉月, 松居 喜郎  肺癌  57-  (1)  48  -48  2017/02  [Not refereed][Not invited]
  
• 外傷性胆嚢損傷の1例

  梅本 一史, 佐藤 暢人, 宮崎 大, 新垣 雅人, 福田 直也, 飯村 泰昭, 長谷川 直人, 平野 聡  日本腹部救急医学会雑誌  37-  (1)  103  -106  2017/01  [Not refereed][Not invited]
   

  症例は29歳,男性。普通自動車運転中にトラックと衝突し受傷した。右股関節脱臼骨折・臼蓋後壁骨折の診断で前医に入院加療中であったが,受傷後5日目に発熱・上腹部痛の増悪を認め,胆嚢炎を疑われ当院へ搬送となった。腹部超音波検査・造影CTで胆嚢の著明な腫大を認め,腹部超音波検査では胆嚢壁が二層に描出され,外傷性胆嚢損傷と診断し同日緊急手術を施行した。診査腹腔鏡で胆嚢壁は虚血性変化を呈し,胆嚢漿膜下には血腫が貯留していたため,開腹手術に移行し胆嚢摘出術を施行した。胆嚢は解剖学的に外力による損傷を受けにくいため,外傷による損傷が比較的まれな臓器である。早期に診断し適切な治療を行えば予後良好な疾患であるが,早期診断が困難な場合があり,治療の遅れにより致命的となり得る。外傷性胆嚢損傷に対しては,超音波検査を中心とした可及的早期の診断と積極的な手術治療が救命に重要である。(著者抄録)
• Comparison of Pulmonary Resection for Lung Cancer after Radical Chemoradiation with That after Induction Chemoradiation

  Yasuhiro Hida, Kichizo Kaga, Masato Aragaki, Reiko Nakada-Kubota, Haruhiko Shiiya, Hatsuki Usui, Yoshiro Matsui  JOURNAL OF THORACIC ONCOLOGY  12-  (1)  S778  -S779  2017/01  [Not refereed][Not invited]
  
• 肺葉切除・区域切除に対するone window & puncture法を用いたreduced port surgeryの検討

  新垣 雅人, 加賀 基知三, 樋田 泰浩, 久保田 玲子, 椎谷 洋彦, 臼井 葉月, 松居 喜郎  日本内視鏡外科学会雑誌  21-  (7)  OS55  -2  2016/12  [Not refereed][Not invited]
  
• 肺癌の新規治療標的としてのLCAS1-LASK1相互作用の同定と機能解析(Characterization of LCAS1-LASK1 pathway as a novel therapeutic target for lung cancer)

  新垣 雅人, 中村 祐輔, 醍醐 弥太郎  日本癌学会総会記事  72回-  263  -264  2013/10  [Not refereed][Not invited]
  
• 非小細胞肺癌におけるCDC20遺伝子の発現と臨床病理学的検討

  加藤達哉, 醍醐弥太郎, 石川慶大, 新垣雅人, 久保田玲子, 樋田泰浩, 加地苗人, 加賀基知三, 松居喜郎  肺癌  52-  (5)  629  -629  2012/10/05  [Not refereed][Not invited]
  
• 肺癌・食道癌の新規診断・治療標的分子LECAP2の同定と機能解析(Identification of LECAP2 as a Prognostic Biomarker and a Therapeutic Target for Lung and Esophageal Cancers)

  新垣 雅人, 土屋 永寿, 平野 聡, 中村 祐輔, 醍醐 弥太郎  日本癌学会総会記事  71回-  190  -190  2012/08  [Not refereed][Not invited]
  
• 非小細胞肺癌におけるKIAA0101遺伝子の発現と臨床病理学的検討

  加藤達哉, 石川慶大, 新垣雅人, 樋田泰浩, 加賀基知三, 松居喜郎, 加地苗人, 醍醐弥太郎  日本呼吸器外科学会総会(Web)  29th-  (3)  P85-05 (WEB ONLY)  -05  2012/04  [Not refereed][Not invited]
  
• 肺癌の新規治療標的分子としてのLCAS1-LASK1キナーゼ経路の同定と機能解析(Identification and characterization of a novel LCAS1-LASK1 kinase pathway as a target for lung cancer)

  新垣 雅人, 醍醐 弥太郎, 角田 卓也, 近藤 哲, 中村 祐輔  日本癌学会総会記事  69回-  167  -167  2010/08
• Dickkopf-1を標的とした新規血清診断バイオマーカーと抗体療法の開発(Dickkopf-1 as a serum biomarker for various human cancers and a molecular target for antibody-based cancer immunotherapy)

  佐藤 暢人, 山吹 匠, 高野 淳, 新垣 雅人, 宮城 洋平, 土屋 永寿, 近藤 哲, 中村 祐輔, 醍醐 弥太郎  日本癌学会総会記事  69回-  400  -400  2010/08  [Not refereed][Not invited]
  
• 肺癌の新規診断・治療標的分子としての癌精巣抗原LASTERの同定と機能解析(Identification of a Novel Cancer-Testis Antigen LASTER as a Prognostic Marker and a Therapeutic Target for Lung Cancer)

  新垣 雅人, 醍醐 弥太郎, 鯉沼 潤吉, 角田 卓也, 土屋 永寿, 近藤 哲, 中村 祐輔  日本癌学会総会記事  68回-  375  -375  2009/08

Association Memberships

• 日本呼吸器外科学会   日本外科学会   日本癌学会   日本胸部外科学会   

Research Projects

• 蛍光スペクトル解析胸腔鏡と5-ALAを応用した新規肺腫瘍マーキング法の開発

  日本学術振興会：科学研究費助成事業 基盤研究(C)

  Date (from‐to) : 2022/01 -2024/03 

  Author : 新垣 雅人, 加藤 達哉, 海老原 裕磨, 櫻井 遊, 樋田 泰浩, 加賀 基知三

   

  5-ALAの含め複数のポルフィリンを主体としたphotosensityzerを使用し、マウスxenograftモデルでの腫瘍集積性を検討した。使用細胞株はヒト肺腺癌細胞株であるA549と扁平上皮癌細胞株であるH2170、またマウス悪性胸膜中脾腫細胞株であるAE17OVAを使用した。投与濃度と投与から解析までの時間を比較検討し、蛍光強度を解析し、至適投与濃度、至適観察時間を確認した。5ALAも含め複数photosensityzerを投与後にマウスxenograftモデルに投与し、生体内のphotosensityzerの他臓器への集積を蛍光強度にて解析した。photosensityzer投与後のマウスxenograftを使用し、腫瘍摘出後に正常ブタ肺の胸膜直下に留置し、正常肺越しに蛍光を確認できるか確認したところ、maestroを使用し確認したところ,5ALAにおいてはblue light excitationによって励起される蛍光は非常に浅い位置に腫瘍を留置した場合でも観察されなかった。現在red light excitationを使用し、蛍光が観察される条件を検討している。比較対象として使用している他のphotosensityzerは671nmのexcitaion lightにて励起されるため、胸膜下の腫瘍からの蛍光が確認できた。 並行してrabbit悪性腫瘍株であるVX2を使用し、rabbit orthotopic modelを作成中である同モデルを使用し、5ALAと他のphotosensityzerの集積性、径胸膜的な蛍光の観察が可能かどうか検討予定である。
• Development of next generation multi-dimensional endoscope system

  Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))

  Date (from‐to) : 2018 -2021 

  Author : Aragaki Masato

   

  We were involved in research and development on ultra thin endoscope, fluorescence, and ultrasound function required for next-generation endoscopes. First of all, we used ultra thin fiber scope made by OK fiber technology and the scanning fiber endoscope, and preliminary experiments on intra-airway observation and photodynamic therapy in mice were performed, and the results were presented. In terms of fluorescence, multiple photosensitizers called ALA, OTL38, Porphysome, and PLP are used to verify whether tumor site identification, photodynamic therapy, and regional lymph node identification are possible with an endoscope, and the results were reported. Regarding ultrasound endoscopy, we have developed and presented a new treatment procedure for pulmonary embolism by Endobronchial Ultrasound Bronchoscopy.